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My PhD three years course in Pharmaceutical Sciences at the Department 
of Pharmacy of Salerno University was started in January 2013 under the 
supervision of Prof. Giuseppe Bifulco. My research activity was mainly 
focused on structural studies, design, identification and biological evaluation 
of anti-inflammatory and antitumor molecules potentially utilizable in therapy 
by means of structure-based drug design, docking studies, QM calculation, 
cell-free assay and cell-based assay. 
These approaches were successfully applied to the identification of new 
chemical platforms targeting microsomal prostaglandin E2 synthase (mPGES-
1), 5-lipoxygenase (5-LOX), cicloxygenase-1 (COX-1), cicloxygenase-2 
(COX-2) and G-protein-coupled purinergic receptors (P2Y12R), acting as anti-
inflammatory and anti-cancer agents. 
The entire work was carried out under the direct supervision of Prof. 
Giuseppe Bifulco. Furthermore, to improve my knowledge in the biological 
field, I moved to the Department of of Pharmaceutical and Medicinal 
Chemistry of the Friedrich- Schiller University in Jena (Juny 2015 until 
February 2016) under the supervision of the Prof. Oliver Werz. During this 
period in his research laboratory, my research work was focused on the 
modulation of 5-LOX activity in the cell-based and cell-free assay, induction 
of mPGES-1 and determination of PGE2 synthase activity in microsomes of 
A549 cells. 
In addition to PhD course activities, I was involved in different side projects, 
mainly regarding the characterization of specific ligand-target interactions 
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Computational methodologies in combination with experimental biological 
assay represent fundamental key tools in the drug discovery process. The study 
of ligand-macromolecule interactions has a crucial role for the design, the 
identification and the development of new chemical platforms as anti-
inflammatory and anti-cancer agents. In this project, different aspects of 
interaction and recognition processes between ligand and targets, and 
stereostructure assignment of natural compounds has been studied through 
different in silico approaches with the determination of their biological 
activities, which allow to corroborate the predicted results. 
In particular, the strong interconnection between the tumoral and 
inflammatory pathology has led to the identification of new promising targets 
involved in essential cellular processes and acting at diverse levels and phases 
of the tumor and inflammation diseases. In this project, the drug design and 
identification of new compounds able to inhibit microsomal prostaglandin E 
synthase mPGES-1, 5-lipoxygenase5-LOX, cicloxygenase-1 COX-1, 
cicloxygenase-2 COX-2 and G-protein-coupled purinergic receptors P2Y12R 
will be described. The results obtained during my PhD three years course can 
be summarized in four main areas of activity, whose relative weight was varied 
according to the development of the overall project: 
1) The support in the design of original scaffolds for the generation of 
libraries potentially utilizable in therapy. This work was conducted in silico 
by molecular docking technique in order to direct the design of the new 
molecules basing on the analysis of ligand-target interactions and the synthetic 
possibilities. This kind of approach was successfully applied leading to the 
identification of new potential inhibitors for mPGES-1 enzyme. The good 





possible the identifications of new lead compounds, rationalizing the molecular 
basis of the target inhibition.  
2) The rationalization of the biological activity of compounds by the 
study of the drug-receptor interactions. Molecular docking was used for the 
detailed study of anti-inflammatory and anticancer compounds whose 
biological activities are known a priori. In fact, thanks to this procedure, in this 
thesis several rationalizations of binding modes were reported related to a small 
pool of natural products as mPGES-1 inhibitors, such as carnosol and carnosic 
acid, and cryptotanshinone and tanshinone IIA as P2Y12R inhibitors. Through 
the in silico methodology the putative binding modes for the reported 
molecules was described offering a complete rationalization of the observed 
biological activities, e.g. evaluating the specific influence of the ligand target 
interactions (e.g. hydrophobic, hydrophilic, electrostatic contacts).  
3) The determination of relative configuration of natural products. The 
complete comprehension of the three dimensional structure of synthetic or 
isolated molecules is fundamental to design and characterize new platform 
potentially utilizable in therapy. On this basis, the combined approach basing 
on the comparison of the predicted NMR parameters (e.g. chemical shifts, 
computed through quantum mechanical (QM) calculations) and the related 
experimentally determined values was employed to assigning the relative 
configuration of giffonins J-P. Moreover, the assignment of relative and 
absolute configuration of giffonins Q-S is ongoing by a combined approach 
that consider the quantum mechanical calculations of circular dicroism spectra 
and quantum mechanical calculations of chemical shifts to be compared with 
the related experimental data. 
4) The biological evaluation and assay systems. The determination of 
PGE2 synthase activity in microsomes of A549 cells, the determination of 
product formation by 5-LOX in the cell-based and cell-free assay and the 





polymorphonuclear leucocytes were performed at the Department of 
Pharmaceutical and Medicinal Chemistry of the Friedrich- Schiller University 
in Jena. Moreover, the preparation of plasma through isolation of monocytes, 






































































































1.1 Inflammation and cancer 
The link between inflammation and cancers, rather than a recent concern, 
was noticed ~150 years ago. As early as 1863, Virchow indicated that cancers 
tended to occur at sites of chronic inflammation.1 
Although it is now clear that proliferation of cells alone does not cause 
cancer, sustained cell proliferation in an environment rich in inflammatory 
cells, growth factors, activated stroma, and DNA-damage-promoting agents, 
certainly potentiates and/or promotes neoplastic risk.  
During tissue injury associated with wounding, cell proliferation is 
enhanced while the tissue regenerates; proliferation and inflammation subside 
after the assaulting agent is removed or the repair completed. In contrast, 
proliferating cells that sustain DNA damage and/or mutagenic assault (for 
example, initiated cells) continue to proliferate in microenvironments rich in 
inflammatory cells and growth/survival factors that support their growth. In a 
sense, tumors act as wounds that fail to heal.2 
Today, the causal relationship between inflammation, innate immunity and 
cancer is more widely accepted; however, many of the molecular and cellular 
mechanisms mediating this relationship remain unresolved. Furthermore, 
tumor cells may usurp key mechanisms by which inflammation interfaces with 
cancers, to further their colonization of the host. Moreover, it was clear that the 
acquired immune response to cancer is intimately related to the inflammatory 
response.3,4 
Here, the critical points and the pathways connections between these two 
kinds of pathologies will be described. 
 
1.1.1 Inflammation: From Acute to Chronic 
Inflammation is a physiologic process in response to tissue damage resulting 
from microbial pathogen infection, chemical irritation, and/or wounding.5 At 





to the inflammatory sites under the regulation of molecules produced by rapidly 
responding macrophages and mast cells prestationed in tissues.6 As the 
inflammation progresses, various types of leukocytes, lymphocytes, and other 
inflammatory cells are activated and attracted to the inflamed site by a signaling 
network involving a great number of growth factors, cytokines, and 
chemokines. All cells recruited to the inflammatory site contribute to tissue 
breakdown and are beneficial by strengthening and maintaining the defense 
against infection. 
There are also mechanisms to prevent inflammation response from lasting 
too long.7 A shift from antibacterial tissue damage to tissue repair occurs, 
involving both proinflammatory and anti-inflammatory molecules. 
Prostaglandin E2,
8 transforming growth factor-α,9 and reactive oxygen and 
nitrogen intermediates6are among those molecules with a dual role in both 
promoting and suppressing inflammation. The resolution of inflammation also 
requires a rapid programmed clearance of inflammatory cells: neighboring 
macrophages, dendritic cells, and backup phagocytes do this job by inducing 
apoptosis and conducting phagocytosis.10 The phagocytosis of apoptotic cells 
also promotes an anti-inflammatory response, such as enhancing the 
production of antiinflammatory mediator transforming growth factor-β11 
However, if inflammation resolution is dysregulated, cellular response changes 
to the pattern of chronic inflammation. In chronic inflammation, the 
inflammatory foci are dominated by lymphocytes, plasma cells, and 
macrophages with varying morphology.5 Macrophages and other 
inflammatory cells generate a great amount of growth factors, cytokines, and 
reactive oxygen and nitrogen species that may cause DNA damage.6a If the 
macrophages are activated persistently; they may lead to continuous tissue 
damage.12 A microenvironment constituted by all the above elements inhabits 
the sustained cell proliferation induced by continued tissue damage, thus 






1.1.2 Cancer Development: An Overview 
Cancer defines malignant neoplasms characterized by metastatic growth. It 
may occur in almost every organ and tissue relating to a variety of etiologic 
factors, such as genomic instability and environmental stress.5 A two-stage 
carcinogenesis model is first conceptualized in a mouse model of skin cancer.13 
In this model, carcinogenesis is initiated by carcinogen-triggered irreversible 
genetic alteration and then promoted by dysregulated gene expression of 
initiated cells that resulted from epigenetic mechanisms and host-selective 
pressure.6a Once the proliferation advantage is obtained, cancer cells enter the 
progression stage in which their population expands rapidly.6b This model was 
subjected to criticism because it oversimplifies and failed to apply to all types 
of cancer.14 
However, cancer development is still accepted as a multistep process, during 
which genetic alterations confer specific types of growth advantage; therefore, 
it drives the progressive transformation from normal cells to malignant cancer 
cells.15 Malignant growth is characterized by several key changes: self-
sufficiency of growth signals, insensitivity to antigrowth signals, escaping from 
apoptosis, unregulated proliferation potential, enhanced angiogenesis, and 
metastasis.15 Each of these shifts is complicated and accomplished by 
combined efforts of various signaling processes, and moreover it will find out 
that inflammation may contribute to the formation of these cancer phenotypes. 
 
1.1.3 Connecting inflammation and cancer 
Common wisdom says ‘‘most things in life are a double-edged sword’’. 
While they are in our favor at one dose or under one condition; they may be 
disfavor at another dose or under another condition. Inflammation is a part of 





response serves to counteract the insult incurred by these stimuli to the host. 
This response can be pyrogenic, as indicated by fever. When acute 
inflammation or fever is manifested for a short period of time, it has a 
therapeutic consequence. However, when inflammation becomes chronic or 
lasts too long, it can prove harmful and may lead to disease. How is 
inflammation diagnosed and its biomarkers is not fully understood, however, 
the role of proinflammatory cytokines, chemokines, adhesion molecules and 
inflammatory enzymes have been linked with chronic inflammation (Figure 
1.1). Chronic inflammation has been found to mediate a wide variety of 
diseases, including cardiovascular diseases, cancer, diabetes, arthritis, 
Alzheimer’s disease, pulmonary diseases, and autoimmune diseases.16 Chronic 
inflammation has been linked to various steps involved in tumorigenesis, 
including cellular transformation, promotion, survival, proliferation, invasion, 
angiogenesis, and metastasis.17,18 That inflammation is a risk factor formost 
type of cancers is now well recognized.19 
 






Al already reported, the links between cancer and inflammation were first 
made in the nineteenth century, on the basis of observations that tumors often 
arose at sites of chronic inflammation and that inflammatory cells were present 
in biopsied samples from tumors,1 but there has been a recent resurgence in 
interest.  
Several lines of evidence20 (Table 1.1) — based on a range of findings, from 
epidemiological studies of patients to molecular studies of genetically modified 
mice — have led to a general acceptance that inflammation and cancer are 
linked. Epidemiological studies have shown that chronic inflammation 
predisposes individuals to various types of cancer. It is estimated that 
underlying infections and inflammatory responses are linked to 15–20% of all 
deaths from cancer worldwide.1 There are many triggers of chronic 
inflammation that increase the risk of developing cancer. Such triggers include 
microbial infections (for example, infection with Helicobacter pylori is 
associated with gastric cancer and gastric mucosal lymphoma), autoimmune 
diseases (for example, inflammatory bowel disease is associated with colon 
cancer) and inflammatory conditions of unknown origin (for example, 
prostatitis is associated with prostate cancer). Accordingly, treatment with non-
steroidal anti-inflammatory agents decreases the incidence of, and the mortality 
that results from, several tumor types.21 
 
Table 1. 1The evidence that links cancer and inflammation 
1 
Inflammatory diseases increase the risk of developing many types of cancer 
(including bladder, cervical, gastric, intestinal, oesophageal, ovarian, prostate 
and thyroid cancer) 
2 
Non-steroidal anti-inflammatory drugs reduce the risk of developing certain 







Signaling pathways involved in inflammation operate downstream of 
oncogenic mutations (such as mutations in the genes encoding RAS, MYC and 
RET). 
4 
Inflammatory cells, chemokines, and cytokines are present in the 
microenvironment of all tumors in experimental animal models and humans 
from the earliest stages of development. 
5 
The targeting of inflammatory mediators (chemokines and cytokines, such 
as TNF-α and IL-1β), key transcription factors involved in inflammation (such 
as NF-κB and STAT3) or inflammatory cells decreases the incidence and spread 
of cancer. 
6 
Adoptive transfer of inflammatory cells or overexpression of inflammatory 
cytokines promotes the development of tumors. 
 
The hallmarks of cancer-related inflammation include the presence of 
inflammatory cells and inflammatory mediators (for example, chemokines, 
cytokines and prostaglandins) in tumor tissues, tissue remodeling and 
angiogenesis similar to that seen in chronic inflammatory responses, and tissue 
repair. These signs of ‘smouldering’ inflammation20a are also present in tumors 
for which a firm causal relationship to inflammation has not been established 
(for example, breast tumors). Indeed, inflammatory cells and mediators are 
present in the microenvironment of most, if not all, tumors, irrespective of the 
trigger for development. 
In the tumor microenvironment, inflammatory cells and molecules influence 
almost every aspect of cancer progress, including the tumor cells’ability to 
metastasize.22 Thus, whereas there were previously six recognized hallmarks 
of cancer — unlimited replicative potential, self-sufficiency in growth signals, 
insensitivity to growth inhibitors, evasion of programmed cell death, ability to 
develop blood vessels, and tissue invasion and metastasis23 — cancer related 
inflammation now emerges as number seven (Figure 1.2). In 2000, 








Figure 1. 2The hallmarks of cancer.  
These are unlimitedreplicative potential, ability to develop blood 
vessels(angiogenesis), evasion of programmed cell death(apoptosis), self-
sufficiency in growth signals, insensitivityto inhibitors of growth, and tissue 
invasion and metastasis.Kim and colleagues’ findings,24 together with those 
ofother studies,22,18 indicate that this model should be revisedto include cancer-
related inflammation as an additionalhallmark.23 
The connection between inflammation and cancer can be viewed as 
consisting of two pathways: an extrinsic pathway, driven by inflammatory 
conditions that increase cancer risk (such as inflammatory bowel disease); and 
an intrinsic pathway, driven by genetic alterations that cause inflammation and 
neoplasia (such as oncogenes) (Figure 1.3).  
The intrinsic pathway was uncovered when addressing why inflammatory 
cells and mediators are present in the microenvironment of most, if not all, 
tumors and therefore are present in cases for which there is no epidemiological 
basis for inflammation. This finding raised the question of whether the genetic 
events that cause neoplasia in these cases are responsible for generating an 





using preclinical and clinical settings in which various oncogenetic 
mechanisms can be assessed. 
The intrinsic pathway is activated by genetic events that cause neoplasia. 
These events include the activation of various types of oncogene by mutation, 
chromosomal rearrangement or amplification, and the inactivation of tumor-
suppressor genes. Cells that are transformed in this manner produce 
inflammatory mediators, thereby generating an inflammatory 
microenvironment in tumors for which there is no underlying inflammatory 
condition (for example, breast tumors). By contrast, in the extrinsic pathway, 
inflammatory or infectious conditions augment the risk of developing cancer 







Figure 1. 3Pathways that connect inflammation and cancer. Cancer and inflammation are 
connected by two pathways: the and the intrinsic extrinsic pathway.  
 
The two pathways converge, resulting in the activation of transcription 
factors, mainly nuclear factor-kB (NF-kB), signal transducer and activator of 
transcription 3 (STAT3) and hypoxia-
cells. These transcription factors coordinate the production of inflammatory 
mediators, including cytokines and chemokines, as well as the production of 





prostaglandins). These factors recruit and activate various leukocytes, most 
notably cells of the myelomonocytic lineage. The cytokines activate the same 
key transcription factors in inflammatory cells, stromal cells and tumor cells, 
resulting in more inflammatory mediators being produced and a cancer-related 
inflammatory microenvironment being generated. Smouldering cancer-related 
inflammation has many tumor-promoting effects. 
 
1.1.3.1  Mutagenic Potential of Inflammation 
The chronic inflammation microenvironment is predominated by 
macrophages.6 Those macrophages, together with other leukocytes, generate 
high levels of reactive oxygen and nitrogen species to fight infection.25 
However, in a setting of continuous tissue damage and cellular proliferation, 
the persistence of these infection-fighting agents is deleterious.6b They may 
produce mutagenic agents, such as peroxynitrite, which react with DNA and 
cause mutations in proliferating epithelial and stroma cells.25,26 Macrophages 
and T lymphocytes may release tumor necrosis factor-α (TNF-α) and 
macrophage migration inhibitory factor to exacerbate DNA damage.27 
Migration inhibitory factor impairs p53-dependent protective responses, thus 
causing the accumulation of oncogenic mutations.28 Migration inhibitory factor 
also contributes to tumorigenesis by interfering Rb-E2F pathway.29 Within an 
ileocolitis-associated mouse cancer model, the high susceptibility to 
inflammation and cancer in hydroperoxide-reducing enzyme-deficient mice 
suggested that intracellular hydroperoxides might also contribute to tumor 
initiation.30 
 
1.1.3.2 Role of Inflammatory Cells in Tumor Development  
Other than a single mutation, more genetic and epigenetic events are 





events are also found to be related to chronic inflammation. For instance, 
angiogenesis, a critical process in tumor progression,31 associates with chronic 
inflammation, such as psoriasis, rheumatoid arthritis, and fibrosis.23 In 
addition, the tumor inflammatory microenvironment can facilitate the breakage 
of the basement membrane, a process required for the invasion and migration 
of tumor cells.6a A wide population of leukocytes and other types of immune 
cells infiltrate to the developing tumor site and establish the tumor 
inflammatory microenvironment.6c Macrophages, neutrophils, eosinophils, 
dendritic cells, mast cells, and lymphocytes are also found to be key 
components in the epithelial-originated tumors.6c,12,32The infiltration of 
immune cells to tumors may repress tumor growth.33 However, the increasing 
concern is that inflammatory cells act as tumor promoters in inflammation-
associated cancers.6a,34,35 Accumulated mutations in epithelial cells lead to 
dysregulation of their growth and migration. These dysregulated epithelial cells 
may also signal to recruit leukocytes.31 In addition, tumor cells may also 
produce cytokines and chemokines to attract immune cells to facilitate cancer 
development.6a,c,31 
 
1.1.3.3 Key Molecular Players in Linking Inflammation to 
  Cancer 
To address the details of transition from inflammation to cancers and the 
further development of inflammation-associated cancers, it is necessary to 
investigate specific roles of key regulatory molecules involved in this process. 
In fact, in the panoply of molecules involved in cancer-related inflammation, 
key endogenous (intrinsic) factors can be identified. These include 
transcription factors (such as NF-kB and signal transducer and activator of 
transcription 3 (STAT3)) and major inflammatory cytokines (such as IL-1β, 






Table 1. 2Key Molecular Players Linking Cancer to Inflammation. 
Potential 
linkers 
Functions in linking inflammation to cancer 
Cytokines  
IL-6 Promote tumor growth 
TNF-α 
Induce DNA damage and inhibit DNA repair 
Promote tumor growth 
Induce angiogenic factors 
Chemokines 
Promote tumor cell growth 
Facilitate invasion and metastasis by directing tumor cell 
migration and promoting basement membrane degradation 
NF-Κβ 
Mediate inflammation progress, promoting chronic 
inflammation 
Promote the production of mutagenic reactive oxygen 
species  
Protect transformed cells from apoptosis 
Promote tumor invasion and metastasis 
Feedback loop between proinflammatory cytokines 
iNOS 
Downstream of NF-nB and proinflammatory cytokines 
Induce DNA damage and disrupt DNA damage response 
Regulate angiogenesis and metastasis 
COX-2 
Produce inflammation mediator prostaglandins 
Promote cell proliferation, antiapoptotic activity, 
angiogenesis, and metastasis 
HIF-1α 
Promote chronic inflammation  
Induced by proinflammatory cytokines through NF-nB  
Enhance the glycolytic activity of cancer cells  
Contribute to angiogenesis, tumor invasion, and metastasis 
by transactivating VEGF 
STAT3 
Activated by proinflammatory cytokines  
Promote proliferation, apoptosis resistance, and immune 
tolerance 





Protect against DNA damage 
NFAT 
Regulate proinflammatory cytokine expression  
Required in cell transformation 
 
For sick of simplicity, between the molecular players involved in 
inflammatory networking cancer, the tumor necrosis factor (TNF-α) and NF-
kB will be described. The TNF-α was first isolated as an anticancer cytokine 
than two decades ago.39 Experience since then has indicated that when 
expressed locally by the cells of the immune system, TNF-α has a therapeutic 
role. However, when dysregulated and secreted in the circulation, TNF-a can 
mediate a wide variety of diseases, including cancer.39 TNF-α has itself been 
shown to be one of the major mediators of inflammation.40 Induced by a wide 
range of pathogenic stimuli, TNF-α induces other inflammatory mediators and 
proteases that orchestrate inflammatory responses. TNF-α is also produced by 
tumors and can act as an endogenous tumor promoter.40 The role of TNF-α has 
been linked to all steps involved in tumorigenesis, including cellular 
transformation, promotion, survival, proliferation, invasion, angiogenesis, and 







Figure 1. 4Inflammatory networking in cancer. 
 
On the other hand, NF-kB is a key coordinator of innate immunity and 
inflammation, and has emerged as an important endogenous tumor promoter.36 
NF-kB is crucial both in the context of tumor or potential tumor cells and in 
the context of inflammatory cells. In these cell types, NF-ΚB operates 
downstream of the sensing of microorganisms or tissue damage by the Toll-
like receptor (TLR)–MyD88 signaling pathway, and by signaling pathways 
mediated by the inflammatory cytokines TNF-α and IL-1β. In addition, NF-kB 
can be activated as a result of cell-autonomous genetic alterations 
(amplification, mutations or deletions)41 in tumor cells. In tumor cells and 
epithelial cells at risk of transformation by carcinogens, as well as in 
inflammatory cells, NF-kB activates the expression of genes encoding 
inflammatory cytokines, adhesion molecules, enzymes in the prostaglandin-
synthesis pathway (such as COX2), inducible nitric oxide synthase (iNOS; also 
known as NOS2) and angiogenic factors. 
In addition, one of the important functions of NF-ΚB in tumor cells or cells 
targeted by carcinogenic agents is promoting cell survival, by inducing the 





evidence of interconnections and compensatory pathways between the NF-KB 
and HIF1α systems,42 linking innate immunity to the response to hypoxia. 
There is unequivocal evidence that NF-ΚB is involved in tumor initiation and 
progression in tissues in which cancer-related inflammation typically occurs 
(such as the gastrointestinal tract and the liver).43 The NF-ΚB pathway is tightly 
controlled by inhibitors that function at various stages of the pathway. An 
example is TIR8 (also known as SIGIRR), a member of the IL-1-receptor 
family. TIR8 has a single immuno globulin domain, a long cytoplasmic tail, 
and a Toll/IL-1 receptor (TIR) domain that differs from that of other members 
of the IL-1-receptor family. Deficiency in the gene that encodes TIR8 is 
associated with increased susceptibility to intestinal inflammation and 
carcinogenesis.44 Thus, the balance of inhibitors and activators tunes the extent 
to which the NF-ΚB pathway operates as an endogenous tumor promoter. 
Support for the connection between cancer and inflammation is further 
strengthened by studies of the role of NF-ΚB in tumor-infiltrating leukocytes. 
In established, advanced tumors, which typically have a microenvironment of 
smouldering inflammation,20 tumor-associated macrophages (TAMs) have 
delayed and defective NF-κB activation.45 Evidence suggests that homodimers 
of the p50 subunit of NF-κB (a negative regulator of the NF-κB pathway) are 
responsible for this sluggish activation of NF-κB in TAMs and for the protumor 
phenotype of these cells.46 Thus, NF-κB seems to function as a ‘rheostat’ whose 
function can be tuned to different levels, a property that enables the extent of 
inflammation to be regulated. Such regulation allows the vigorous 
inflammation (for example, in inflammatory bowel disease) that predisposes 
individuals towards developing cancer to be sustained, and enables TAMs to 
sustain the smouldering inflammatory microenvironment present in established 
metastatic neoplasia.  
Briefly, the mediators and cellular effectors of inflammation are important 
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2. Derived-NSAIDs side effects and the necessity to discover 
new safe targets 
Non steroidal anti-inflammatory drugs (NSAIDs) represent so far the pivot 
of inflammation therapy as a consequence of their potent effect in the 
suppression of prostaglandins (PGs), prominent bioactive mediators involved 
in key physiological functions and also implicated in several pathologic 
conditions like inflammation and tumorigenesis. However, especially for long-
term treatments - like those required for chronic pathologies such as 
rheumatoid arthritis - their use comprises severe side effects; in particular 
NSAIDs are well known to be endowed with relevant gastric toxicity due to 
the efficient suppression of constitutively generated PGs involving the COX-1 
pathway with gastro-protection function. Not long ago, the introduction of 
coxibs in therapy was initially considered as a solution of all the problems 
connected with the use of NSAIDs, as these selective COX-2 inhibitors showed 
to exhibit potent anti-inflammatory activity without causing significant 
gastrointestinal injury. Unfortunately, several clinical evidences indicated their 
implication in serious cardiovascular accidents. Given the known effects of 
PGs on cardiovascular function, there has been concern of the potential for 
cardiotoxicity with any inhibitor of PG biosynthesis as anticancer agents. For 
example, prostacyclin synthase is expressed in endothelial cells, its product, 
PGI2, is known for its cardio-protective properties that cause platelet de-
aggregation and vessel dilation.47 For example, a study in patients taking 
selective COX-2 inhibitors showed that the increased risk of myocardial 
infarction (MI) and stroke,48,49 and increased mortality after MI50 may be due 
to an imbalance of prothrombotic eicosanoids (increased TXA2) and 
antithrombotic eicosanoids (decreased PGI2).
51 
In this perspective, there is an ever growing need for the research of safer 
anti-inflammatory drugs. Recently, great attention has been focused on the 





enzyme is over-expressed in several inflammatory disorders as well as in many 
human tumors. Elevated levels of mPGES-1, in fact, are often observed 
concomitantly with COX-2 over-expression. In fact, in vitro studies have 
demonstrated that mPGES-1 is localized at the perinuclear membrane and 
endoplasmic reticulum and is in general functionally coupled with COX-2, 
thereby enabling efficient generation of PGE2 during inflammation. Moreover, 
recent studies have shown that mPGES-1 expression can be specifically 
induced by lipopolysaccharide (LPS) in rat peritoneal macrophages, 
interleukin-1b (IL-1β) and tumor necrosis factor (TNF)-α in a human lung 
carcinoma cell line, A549 with or without induction of COX-2.52,53,54 However, 
studies with these diverse stimuli have clearly shown that mPGES-1 can also 
be functionally activated in the absence of induced COX-2 levels, providing 
evidence that these two enzymes can be independently regulated. This latter 
observation is important from the standpoint of drug targeting. It suggests the 
possibility that the enzymatic activity of mPGES-1 can be pharmacologically 
targeted with resultant suppression of PGE2 production by mechanisms that 
circumvent the toxicity associated with inhibition of COX-2 activity. 
Interestingly, the deletion of mPGES-1 did not have impact on blood pressure 
when the mice were crossed with low-density lipoprotein receptor (LDLR) 
knockout mice.55 Moreover, Wu et al.56 demonstrated absence or reduced 
levels of myocardial damage after coronary occlusion in mice lacking mPGES-
1 compared to mice given COX-2 inhibitor (celecoxib).57 However, in contrast 
to work with COX-2 inhibitors mice with targeted deletion of the gene 
encoding mPGES-1 did not show any alteration the levels of TXA2 or PGI2 in 
the heart after MI. Therefore, pharmacological inhibition of mPGES-1 may not 
be associated with the perturbations in TXA2 and PGI2 metabolism that 
increase the risk of arterial thrombosis in patients taking COX-2 inhibitors. 
Moreover, it was recently reported by Cheng et al.58 that mPGES-1 deletion, in 





hypertension or a predisposition to thrombosis in normolipidemic mice.58 The 
controversial discussion about the pharmacological potential of mPGES-1 as 
safe drug target reached its peak after inhibition of mPGES-1 has been shown 
to redirect the COX product and mPGES-1 substrate PGH2 towards the 
biosynthesis of other PGs. The blockage of mPGES-1 either elevated levels of 
thromboxane (Tx)B2, PGI2 and/or PGD2 or was without effect depending on 
the cell type- and tissue-specific expression pattern of PGs synthases. The 
redirection of PGH2 is not necessarily detrimental. The increase of PGI2 
production, for example, might even be advantageous for the cardiovascular 
safety of mPGES-1 inhibitors. Meanwhile, multiple cellular and animal studies 
have drawn a more complete picture about the physiological interrelations of 
mPGES-1 as described in several excellent reviews. These important findings 
suggest that selective mPGES-1 inhibitors should have very low, if any, 
cardiotoxic side effects typically associated with COX-2 inhibitors.  
 
2.1 mPGES-1 as new molecular target for the treatment of 
inflammation and cancer 
mPGES-1 is the terminal inducible synthase responsible for the production 
of protumorigenic PGE2 and it is overexpressed in a variety of 
cancers.59,60,61,62,63,64 It is a member of the membrane-associated proteins 
involved in eicosanoid and glutathione metabolism (MAPEG) superfamily and 
exhibits a significant sequence homology with microsomal glutathione-S-
transferase (GST)-1-like 1 (MGST-1), 5-lipoxygenase (LOX)-activating 
protein (FLAP) and leukotriene C4 synthase (LTC4S). All MAPEG proteins 
are small proteins of 14–18 kDa and have a similar 3D structure. Hence, 
mPGES-1 is the terminal enzyme in the biosynthesis of PGE2 (Figure 2.1). In 
the first step, membrane-bound and secretory phospholipase A2 (PLA2) 
isoforms convert phospholipids (PL) to arachidonic acid (AA). Next, the COXs 





isomerize PGH2 into PGE2. PGH2 is the precursor for several structurally 
related PGs, which are formed by the action of specialized prostaglandin 
synthases. The PGs synthesized by this pathway include the before-mentioned 
PGE2, as well as prostaglandin D2 (PGD2), prostaglandin F2α (PGF2α), 
prostaglandin I2 (PGI2, also known as prostacyclin) and thromboxane A2 
(TXA2) (Figure 2.3). Consequently, it is thought that inhibition of COX-2 
activity affects the synthesis of all prostanoids down-stream of PGH2, whereas 
selective targeting of mPGES-1 would only reduce PGE2 production. It should 
be noted that shunting towards other PG has been observed and that dual 
inhibitors for the 5-LOX and mPGES-1 are considered as a novel excellent 
avenue to inhibit the pathway. 
 






Microsomal prostaglandin E synthase-1 expression is low in most normal 
tissues, although abundant and constitutive expression is detected in a limited 
number of organs, such as the lung, kidney and reproductive organs. The 
induction of COX-2 and mPGES-1 by pro-inflammatory factors and their 
cooperation in converting AA to PGE2 in vitro suggests that both enzymes are 
important for PGE2 biosynthesis and that inhibition of either is sufficient to 
inhibit PGE2 production. The kinetics of induction of mPGES-1 and COX-2 
has been reported65 to be different suggesting a differential regulation of the 
enzymes. mPGES-1 expression can be specifically induced by LPS, IL-1β and 
TNF-α in various cell types with or without induction of COX-2. The putative 
promoter of human mPGES-1 gene is GC-rich, lacks a TATA box and contains 
binding sites for C/EBP and AP-1, two tandem GC boxes, two progesterone 
receptor and three GRE elements.66 Of these sites, the GC boxes are critical for 
the promoter activity where the transcription factor early growth response 
protein 1 (Egr-1) binds to the proximal GC box and triggers mPGES-1 
transcription. Mice genetically deficient in mPGES-1 have shown that the 
enzyme is a key mediator of inflammation, pain, angiogenesis, fever, bone 
metabolism and tumorigenesis, thus making this protein an attractive target for 
the treatment of osteoarthritis, rheumatoid arthritis, acute or chronic pain and 
cancer, which is the focus of this review. In 2003, the role of mPGES-1 in 
inflammatory and pain response was first studied.67 The authors generated 
mPGES-1-deficient trans-genic mice and showed that reduced expression of 
mPGES-1 leads to decrease in writhing, an indicator of inflammatory pain. 
Other reports have further concluded that mPGES-1 is indeed involved in 
various types of inflammation, including pain hyperalgesia, granulation 
associated with angiogenesis, and inflammatory arthritis accompanying bone 
destruction. However, using the acetic acid stretching test with or without LPS 





profoundly to LPS-primed inflammatory hyper-algesia than to basal acute pain 
perception.68 
 
2.1.1. The solved mPGES-1 crystal structures 
An electron crystallographic structure (3.5 Å) of mPGES-1 was published 
in 2008 (PDB code: 3DWW)69 and confirmed the trimeric structure of the 
protein as predicted by Xing et al.70 and suggested by Hetu et al.71. The enzyme 
might switch between two conformations45 as previously described for LC4S. 
Similarly to MGST-1, FLAP and LTC4S, the protein folds into four 
transmembrane helices (TM1–4). The centre of the mPGES-1 trimer consists 
of a funnel-shaped cavity, which opens towards the cytoplasm and expands 
well into the transmembrane region. Subsequently, the protein was crystallized 
in the presence of GSH (PDB: 4AL1),72 which binds in the active site of the 
enzyme defined mostly by TM1 and TM4 for each of the subunits (Figure 2.1.1 
and 2.1.2). GSH interacts in a ‘U-shape’ mainly with Arg126, Arg110 and 
Glu77 from TM4 and His72 from TM1 of another subunit. Since COX 
generates PGH2 at the luminal side of the endoplasmic reticulum, PGH2 has to 
diffuse through the membrane for transfer to mPGES-1. PGH2 is believed to 
enter the active site pocket with its peroxofuran head group. The two flexible 
aliphatic chains of PGH2 protrude from the pocket and might be inserted into 






Figure 2. 1. 1Tridimensional model of mPGES-1 in complex with GSH. 
 
It should be stressed that the mPGES-1 structure obtained by Jegerschöld et 
al.69 represents a closed conformation of the protein. A model of the open 
conformation reveals that prostaglandin endoperoxide (PGH2) could fit into the 
cleft defined by TM1 and TM4, allowing the synthesis of PGE2.  
 
 








The homology model published by Xing et al.70 predicted a 3:3 binding 
stochiometry of mPGES-1 and its substrate. A co-crystal of mPGES-1 with a 
small-molecule inhibitor LVJ (I) (PDB code: 4BPM)73 would confirm these 
previous predictions and facilitate drug design for this interesting therapeutic 
target (Figure 2.1.3).  
 
Figure 2. 1. 3 Chemical structure of LVJ (I) in 4BPM. 
 
The most recent crystal structures of mPGES-1 bound to four distinct 
specific potent small molecule inhibitors (Figure 2.1.4), providing a rationale 
for understanding the associated structure−activity relationships and a 
structural context for species-associated selectivities.74 The four scaffolds 
presented in complex with mPGES-1 are a biarylimidazole (II),75 a 
phenanthrene imidazole (MF63, III),76 and two biarylindoles (IV, V).77,78 A 
general binding mode is observed in which inhibitors pack against the fourth 
helix of the first monomer while placing head groups into a critical pocket 
formed above the GSH. While a strong tendency to interact with α-4 of 
monomer 1 is observed, there is clear potential to access contacts with α-1 of 
monomer 2 in a possible alternative binding mode. A side from the 





α-1 that could potentially contribute to ligand binding are conserved between 
the rat and human sequences, implying that inhibitors utilizing such 
interactions might be less species-dependent with respect to potency. The tail 
end of the inhibitors, opposite the head group which binds in the pocket above 
GSH, is largely exposed to solvent in the crystal structures, implying that 
modifications of the inhibitor tails likely improve potency through nonspecific 
means. 
 
Figure 2. 1. 4 Structures of co-crystallized inhibitors biarylimidazole (II), MF63 
(III),and two biarylindoles (IV-V) in 4YK5.  
 
Of note are also the structural similarities with other crystallized proteins) 
such as the Huntingtin interacting protein 12 (PDB code: 1R0D), the V-type 





kinase 2 β (β3GM3). Part of these structural similarities should be taken in 
consideration perhaps when selective inhibitor design is undertaken.  
 
2.1.2. Known mPGES-1 inhibitors 
There are several examples of compounds that were identified and 
developed to target mPGES-1, that have been described in the literature 
classified into three different categories: endogenous lipid, fatty acids and 
PGH2 analogs; known anti-inflammatory drugs and/or inhibitors of 
leukotrienes (LTs) biosynthesis; and natural compounds.79 Compounds that 
were further improved based on their structure and cellular activities are also 
described in the next section.  
 
2.1.2.1. Endogenous lipid, fatty acids and PGH2 analogues 
It has been reported that mPGES-1 is weakly inhibited (IC50 = 5 μM) by 
cysteinyl leukotriene C4 (LTC4), which also inhibits the structurally related 
MGST-1 with higher potency (IC50 = 50 nM). With a GSH moiety, LTC4 has 
been shown to inhibit MGST-1 by competing with GSH. Because of the 
structural homology between the members of MAPEG family of enzymes, 
inhibition of mPGES-1 activity by LTC4 may be due to a similar mechanism. 
Other lipid mediators such as PGs have also been tested for mPGES-1 
inhibition. The anti-inflammatory 15-deoxy-Δ 12,14-PGJ2 is found to be the 
most potent inhibitor of mPGES-1 (IC50 = 0.3 μM) compared with PGE2, 
PGF2α, TXB2 and PGJ2. The fact that 15-deoxy-Δ 12,14-PGJ2 is much more 
potent than its analogs PGJ2 or Δ 12-PGJ2 (IC50> 50 μM) suggests that the 
hydroxyl group at C15 position impairs mPGES-1 inhibition. Besides naturally 
occurring PGs, stable PGH2 analogs have also been tested as potential mPGES-
1 inhibitors, among which U-51605 inhibits mPGES-1 activity to some extent. 
However, the potency is inconsistent between the studies. Unlike U-51605, two 





activity of mPGES-1 is also inhibited by a number of fatty acids such as AA, 
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) (IC50 = 0.3 μM for 
each), and palmitic acid (IC50 = 2 μM). These results suggest that the anti-
inflammatory properties of 15-deoxy-Δ 12,14-PGJ2, DHA and EPA can be 
partly attributed to mPGES-1 inhibition. 
 
2.1.2.2. Known anti-inflammatory drugs and/or inhibitors 
of leukotrienes (LTs) biosynthesis 
The only traditional nonsteroidal anti-inflammatory drug (NSAID) that 
exhibits inhibitory effect for mPGES-1 is sulindac. Its active metabolite 
sulindac sulfide has been shown to weakly inhibit mPGES-1 activity (IC50 = 
80 μM). There are several examples of selective COX-2 inhibitors that also 
found to inhibit mPGES-1 activity. For instance, NS-398 is a COX-2 inhibitor 
that also inhibits mPGES-1 with an IC50 value of 20 μM. Similarly, some other 
coxibs such as celecoxib (IC50 = 22 μM), lumiracoxib (IC50 = 33 μM), and 
valdecoxib (IC50 = 75 μM) also moderately inhibit mPGES-1 activity, whereas 
the other tested coxibs (etoricoxib and rofecoxib) fail to inhibit mPGES-1 
activity even when used up to 200 μM. Interestingly, the celecoxib derivative 
dimethylcelecoxib (DMC) loses the COX-2 inhibitory effect, while obtaining 
slightly better potency for mPGES-1 inhibition (IC50 = 16 μM) as measured in 
a cell-free assay. MK-886, an LT suppressor acting through inhibition of FLAP 
(IC50 = 26 nM), is also found to inhibit mPGES-1 in vitro (IC50 = 1.6 μM).
80,81 
This result reinforces the similarity among the members of MAPEG (mPGES-
1 versus FLAP). In intact cells, however, MK-886 has limited inhibitory effects 
on PGE2. At 100 μM, MK-886 only slightly reduces (~20%) LPS-induced 
PGE2 in human whole-blood, and does not show further inhibition with higher 
concentration. In cytokine-stimulated gingival fibroblasts, MK-886 does not 





mPGES-1 is slightly reduced. When used at higher concentration (8 μM), it 
even increases PGE2 production in these gingival fibroblasts, with a 
concomitant upregulation of COX-2 protein. In Caco-2 and HT-29 colon 
cancer cells, 10 μM of MK-886 significantly increases PGE2 production, which 
may be due to a shunt of AA metabolism to the PG pathway, since MK-886 is 
an inhibitor targeting the 5-LOX pathway. Taken together, the lack of 
inhibitory effect of MK-886 on cellular PGE2 synthesis suggests that this 
compound is unlikely to serve as an mPGES-1 inhibitor in vivo to reduce PGE2 
production. Nevertheless, MK-886 has been used as a basis for the 
development of more potent and selective mPGES-1 inhibitors.  
 
2.1.2.3. Natural compounds 
Another anti-inflammatory drug licofelone (ML3000), originally identified 
as a dual inhibitor blocking both COX and 5-LOX pathways, has also been 
shown to inhibit mPGES-1 activity with an IC50 value of 6 μM. It dose-
dependently reduces PGE2 production (EC50= 0.1 μM) in IL-1β-stimulated 
A549 cells, a system where COX-1 is undetectable, without affecting the 
generation of PGI2 (as detected by its stable metabolite 6-keto PGF1α using an 
ELISA assay). However, the in vivo effect of licofelone on PGE2 reduction is 
also contributed by COX-1 inhibition, because licofelone is a potent COX-1 
inhibitor as tested in vitro (IC50 = 0.8 μM) and in intact human platelets (EC50 
= 0.24 μM) for 12-hydroxy-5,8,10-heptadecatrienoic acid (12-HHT) reduction. 
Interestingly, it has been shown by flexible alignment that licofelone shares 
pharmacophore features with MK-886. In line with this observation, it acts 
primarily on FLAP rather than 5-LOX itself. Licofelone is currently evaluated 
as a treatment for osteoarthritis, as it can suppress both PGE2 and LTs 
biosynthesis, which offers benefits over traditional NSAIDs and selective 





selective mPGES-1 inhibitors by further structure–activity relationship (SAR) 
studies.  
 
2.1.3. Future challenge 
An exponential increase in the number of papers on mPGES-1 can be 
noticed since its discovery and clearly the pathway and the enzyme have 
generated a great interest in the field of research. Papers that describe small 
molecules that inhibit the activity of the enzyme have increased dramatically 
over the past 5 years. This observation can further be followed in the number 
of patents issued over these past 5 years as well. GRC27864 is the only potent, 
selective, orally bioavailable inhibitor that has successfully completed pre-
clinical and phase 1 enabling studies. However, and interestingly, compounds 
that are subsequently found to inhibit mPGES-1 in cell-free assays and/or in 
vitro cellular assays, have been reported to exhibit in vivo anti-inflammatory 
activity only in rare cases in various animal models. One may wonder as to the 
explanation of such observation. There are several facts that could explain this. 
First, selectivity could be one of them, thus, compounds that will inhibit the 
target will likely hit the other members of the family. The fact that one subunit 
of mPGES-1 also resembles other proteins such as the Huntingtin interacting 
protein 12 (PDB: 1R0D), the V-type sodium ATP synthase subunit K (PDB: 
2BL2) or the protein tyrosine kinase 2 β (b3GM3) is also concerning. Only 
MK-886 has been demonstrated to exhibit some anticancer properties in vivo, 
mostly due to its FLAP inhibitory properties. However, increasing evidences 
suggest that dual inhibitors such as 5-LOX/mPGES-1 inhibitors would work 
well but clinical trials will further validate this novel concept. Second, amino 
acid sequence disparities between human, mouse and rat may have impaired 
research. Finally, from a modeling as well as a drug design point of view, the 
trimeric target possess a very hydrophobic active site and has been proposed to 





complications encountered during the development and/or discovery of novel 
selective inhibitors for mPGES-1.82  
In conclusion, it is clear that mPGES-1 represents an attractive therapeutic 
target for cancer as well as other disease in which inflammation plays a role. 
How soon will a mPGES-1 inhibitor be identified and tested in clinical trials 
will depend on the co-crystallization of a lead compound within the active 
recently gained and the selectivity that can be achieve within the MAPEG 
family of enzymes. 
 
2.2 Dual inhibition of 5-LOX/mPGES-1 as new molecular 
target for the treatment of inflammation and cancer 
Although high selectivity is generally one of the primary aims in the 
development of mPGES-1 inhibitors, the targeted discovery of agents that 
besides mPGES-1 also interfere with 5-LOX has been pursued in parallel, and 
various chemical scaffolds have been identified that dually suppress mPGES-
1 and 5-LOX. Such simultaneous suppression of PGE2 and leukotrienes might 
be a valuable pharmacological strategy to intervene with inflammatory 
disorders and is expected to have beneficial effects over single interference, not 
only in terms of better efficacy but also in view of a reduced incidence of side 
effects.83,84 The well-recognized shunting of arachidonic acid derived lipid 
mediator biosynthesis towards leukotrienes due to suppression of PG formation 
by COX inhibitors (which cause NSAID-induced asthma) can be circumvented 
by dual COX/5-LOX inhibitors that had been developed already 20 years ago. 
The disadvantage of dual COX/5-LOX inhibitors, however, concerns the 
suppression of beneficial prostanoids such as antithrombotic and vasodilatory 
PGI2, but also of gastrointestinal-protective PGE2. Accordingly, agents that 
mainly suppress the formation of pro-inflammatory ones (i.e., “inducible” 
PGE2, leukotriene B4 and cysteinyl-leukotrienes) among all eicosanoids may 





mPGES-1/5-LOX inhibitors may have this potential. On this basis, the 
increasing evidences suggest that dual inhibitors such as 5-LOX/mPGES-1 
inhibitors would work well but clinical trials will further validate this novel 
concept. 5-Lipoxygenase (5-LOX), a non-haeme iron-containing dioxygenase, 
initiates the biosynthesis of leukotrienes (LTs) from arachidonic acid (AA) and 
it is responsible of the synthesis of anti-inflammatory lipoxins. LTs are 
involved in the pathogenesis of asthma and allergic rhinitis, but may also play 
a role in atherosclerosis and cancer. Upon cell stimulation, the cytosolic PLA2 
(cPLA2) releases AA that is converted by the enzyme 5-LOX into LTA4. The 
conversion of AA induced by 5-LOX is facilitated by the nuclear membrane 
bound 5-LOX-activating protein (FLAP), which will ultimately determine the 
biosynthesis of the LTs. LTA4 is then converted to other LTs (i.e. LTB4 or 
cysteinyl-LTs) by LTA4 hydrolase or LTC4 synthase, depending on the cell 
type. LTB4 acts as potent pro-inflammatory agent by inducing chemotaxis and 
activation of leukocytes, whereas the cys-LTs essentially cause vaso and 
bronchoconstriction. Because of the significant pathophysiological role of LTs, 
pharmacological concepts have been developed to either block the action of 
LTs or to inhibit their biosynthesis. Inhibition of cPLA2 or of 5-LOX as well 
as competition with FLAP are effective pharmacological strategies that 
interfere with LT biosynthesis and there are currently novel 5-LOX and FLAP 
inhibitors undergoing clinical trials. Similar to mPGES-1, the expression and 
activity of 5-LOX have been found to be up-regulated in many cancer cell lines, 
and closely related to tumor size, depth and vessel invasion. It is evident from 
recent studies that 5-LOX and its downstream products leukotriene B4 (LTB4) 
and 5-hydroxyeicosatetranoic acid (5- HETE) could enhance cell proliferation 
and suppress apoptosis, thereby promoting the development of carcinogenesis. 
It seems likely that mPGES-1 and 5-LOX may represent an integrated system 
that regulates the proliferation, metastatic and proangiogenic potential of 





rational concept for the design of more efficacious anti-flammatory and 
antitumoral agents with an improved safety profile. Dual inhibitors that block 
both mPGES-1 and 5-LOX metabolic pathways of arachidonic acid are 
expected to possess clinical advantages over the selective inhibitors of enzyme  
 
 
2.2.1. Human 5-LOX stabilized crystal structure 
5-LOX activity is short-lived, apparently in part due to an intrinsic 
instability of the enzyme. The 5-LOX-specific destabilizing sequence is 
involved in orienting the carboxy-terminus which binds the catalytic iron. The 
crystal structure at 2.4 Å resolution of human 5-LOX stabilized was reported 
by replacement of this sequence.85 Leukotrienes (LT) and lipoxins are potent 
mediators of the inflammatory response derived from arachidonic acid (AA). 
When leukocytes are activated, arachidonic acid is released from the nuclear 
membrane by the action of cytosolic phospholipase A2 and binds 5-
lipoxygenase-activating protein (FLAP). The increased Ca2+ concentration of 
the activated cells simultaneously promotes translocation of 5-LOX to the 
nuclear membrane where it acquires its substrate from FLAP. Arachidonic acid 
(AA) is converted to leukotriene (LTA4) in a two-step reaction which produces 
the 5S-isomer of hydroperoxyeicosatetraenoic acid (5S-HPETE) as an 
intermediate. Auto-inactivation of 5-LOX activity has been described, and this 
loss of activity is perhaps important in limiting the synthesis of its pro- and 
anti-inflammatory products. Previous reports indicate that non-turnover based 
inactivation is a consequence of an O2 sensitivity linked to the oxidation state 
of the catalytic iron. However, not all LOXs display this hypersensitivity to O2. 
For example, 8R-LOX activity is stable despite a solvent exposed iron 
coordination sphere equivalent to that in 5-LOX. In similar conditions 50% of 
5-LOX activity is lost in 10 hours. We reasoned that 5-LOX specific 





inactivation. Regulatory mechanisms that facilitate transient activation include 
targeted degradation, phosphorylation, and allosteric control of enzyme 
activities. Auto-inactivation as a consequence of intrinsic protein instability 
may play a similar role. For example, the instability of the tumor suppressor 
protein p53, relative to its orthologs such as p73, has been proposed to have a 
functional role. 
 
2.2.2. Known 5-LOX inhibitors 
5-LOX inhibitors are classified into: redox-type inhibitors that interfere with 
the redox cycle of the active-site iron; iron ligand-type inhibitors that chelate 
the active-site iron; non-redoxtype inhibitors that compete with AA and/or fatty 
acid hydroperoxides and ‘novel type’ 5-LOX inhibitors with distinct modes of 
action. However, only zileuton, an iron ligand-type 5-LOX inhibitor of the N-
hydroxyurea series developed by Abbott, has been approved as a LT synthesis 
inhibitor for pharmacotherapy. Zileuton reportedly inhibits 5-LOX via iron 
chelation but is devoid of 12- and 15-LOX inhibitory activity.86 A78773 proved 
to be more potent than Zileuton both in vitro and in vivo. A78773 was 30-fold 
more potent than Zileuton in the ionophore-stimulated neutrophil assay. One 
of the most widely studied redox inhibitors is docebenone or 2,3,5-trimethyl-
6-(12-hydroxy-5,10- dodecadiynyl)-1,4-benzoquinone (AA-861), a lipophilic 
quinone structurally resembling coenzyme Q developed by Takeda Chemical 
Industries, Ltd. (Osaka, Japan). AA-861 is a potent competitive inhibitor of 5-
LOX but has no effect on either 12-LOX or COX at concentration 10 mM. 
ZD2138 by Zeneca, a selective, p.o.- active 5-LOX inhibitor of the 
methoxytetrahydropyran series, is devoid of redox and iron ligand-binding 
properties. Despite its promising anti-inflammatory profile, Phase II clinical 
trials carried out in asthmatics had mixed results, halting further clinical 





derived from COX inhibitors indomethacin and sulindac led to development of 
MK-886 by Merck, the first FLAP inhibitor to reach clinical evaluation. MK-
886 is believed to work by binding to an arachidonic acid binding site on FLAP, 
facilitating the transfer of the substrate to 5-LOX. Optimization of the 2-
quinolylmethyloxy phenyl residue of Revlon’s REV 5901 led to BAY-X1005, 
a potent, p.o. active inhibitor of 5-LOX developed by Bayer AG to treat asthma. 
BAY-X1005 reportedly lacks 12-LOX or COX inhibitory activity and is 
devoid of antioxidant activity. SC 41930, a potent first generation LTB4 
receptor antagonist developed by Searle (Monsanto) has demonstrated potency 
in a variety of inflammatory models. However, the discovery that SC 41930 
inhibits f-MLP-induced superoxide release prompted further research to 
develop agents with greater potency and selectivity. Ultair (Pranlukast, ONO-
1078, SB205312) or N-(4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl)-4-
(4-phenylbutoxy)-benzamide, licensed from Ono Pharmaceuticals by 
Smithkline Beecham, is the first LTD4 antagonist to be introduced in the world, 
having been approved to treat asthma in Japan in 1995; it is now in Phase III 







Figure 2. 1. 1 Binding site of 5-LOX. 
 
2.2.3. Dual inhibitors of mPGES-1 and 5-LOX  
As mentioned before, suppression of both LTs and PGs biosynthetic 
pathways might be more advantageous than single interference with 
prostaglandins formation, in terms of anti-inflammatory effectiveness and of 
reduced incidence of gastrointestinal and cardiovascular side-effects showed 
by the traditional NSAIDs and coxibs, respectively. This assumption paved the 
way for the development of a new class of molecules able to inhibit both 
mPGES-1 and 5-LOX. Within this class we can include MK-88680 and related 
derivatives81, pirinixic acid analogues and acylphloroglucinols. MK-886 and 
its derivatives seem to interfere with cellular PGE2 biosynthesis also through 
other mechanisms different from a direct inhibition of mPGES-1. For example, 
they were proved to interfere with several members of the MAPEG family 





amino acid motif within this family, in the MK-886 binding pocket of FLAP. 
Furthermore, licofelone, currently undergoing phase III trials for osteoarthritis, 
showed potent anti-inflammatory properties in clinical and pre-clinical studies 
lacking gastrointestinal toxicity. This activity has been related to the 
simultaneous inhibition of COX-1, mPGES- 1 and 5-LOX. The dual mPGES-
1 and 5-LOX pirinixin acid derivatives inhibitors were synthesized starting 
from the PPARγ agonist WY-14,643. The structural optimization of this lead 
compound led to the discovery of the potent carboxylic acid which represents 
the most potent dual inhibitor within this series (mPGES-1: IC50 = 1.3 µM; 5-
LOX: IC50 = 2 µM). Finally among the acylphloroglucinols noteworthy are 
myrtucommulone (mPGES-1: IC50 = 1.0 µM; 5-LOX: IC50 ˂ 30µM) from 
myrtle, hyperforin (mPGES-1: IC50 = 1.2 µM; 5-LOX: IC50 = 0.09 µM) from 
St. John‟s wort and garcinol (mPGES-1: IC50 = 0.3-1.2 µM; 5-LOX: IC50 = 0.1 
µM). Their activity seems to be connected with the presence of 
acylphloroglucinol core which itself is hardly active (IC50> 30 µM).  
 
2.3 Scope and outline 
The study of ligand-macromolecule interactions has a fundamental role for 
the design and the development of new and more powerful platforms as anti-
inflammatory and anticancer drugs. In this project, different aspects of 
interaction and recognition processes between ligand and macromolecule has 
been studied through a combined approach based on computational chemistry 
techniques and biological assays. In particular, the computational aspects 
regard the employment and elaboration of screening methods, the analysis of 
structural determinants responsible of drug-macromolecule interaction and the 
design and development of new potent bioactive compounds by means of 
docking calculations. For what concern the biological part, the determination 
of PGE2 synthase activity in microsomes of A549 cells, the determination of 





determination of eicosanoids production by LC-MS/MS in monocytes and 
polymorphonuclear leucocytes were performed at the Department of of 
Pharmaceutical and Medicinal Chemistry of the Friedrich- Schiller University 
in Jena. Moreover was carry out the preparation of plasma through isolation of 
monocytes, polymorphonuclear leucocytes and platelets. 
Several and different proteins, involved in essential cellular processes, have 
been investigated as biological targets taking into account their implication in 
tumor and inflammation initiation and progress with the aim to identify and 
rationalize new molecules potentially utilizable in therapy. As already reported, 
in some types of cancer, inflammatory conditions are present before a 
malignant change occurs. Conversely, in other types of cancer, an oncogenic 
change induces an inflammatory microenvironment that promotes the 
development of tumors. Regardless of its origin, inflammation in the tumor 
microenvironment has many tumor-promoting effects. It aids in the 
proliferation and survival of malignant cells, promotes angiogenesis and 
metastasis, subverts adaptive immune responses, and alters responses to 
hormones and chemotherapeutic agents. The molecular pathways of this 
cancer-related inflammation are now being unraveled, resulting in the 
identification of new target molecules that could lead to improved diagnosis 
and treatment. In particular, the inhibition of mPGES-1 has been proposed as a 
more promising approach for the development of safer drugs for cancer 
suppression and in inflammatory disorders87,88 devoid of classical NSAID side 
effects, as this inducible enzyme affects the biosynthesis of massive PGE2 
generation as a response to inflammatory stimuli.89 Among the three isoforms 
so far identified for PGES, it is mPGES-1, functionally coupled with COX-2, 
which seems to be the isoform primarily involved in pathologies.89 Increasing 
evidences suggest that farther dual inhibitors such as 5-LOX/mPGES-1 
inhibitors would work well but clinical trials will further validate this novel 





(microsomal prostaglandin E synthase, mPGES-1; 5-lipoxygebase, 5-LOX; 
cicloxygenase-1, COX-1; cicloxygenase-2, COX-2; G-protein-coupled 
purinergic receptors, P2Y12R) with different mechanisms of action involved in 
diverse levels and phases of tumor and inflammation process.  
mPGES-190 is becoming a target for cancer suppression thanks to its 
inhibitory ability to suppress the PGE2 synthesis offering the potential for 
therapeutic benefit without the potential toxicity associated with COXs 
inhibition. In particular, in the chapter 3 the results obtained by the design and 
the biological evaluation of new synthetic platforms targeting mPGES-1 and/or 
acting as dual inhibitor of mPGES-1/5-LOX were discussed. The elucidation 
of new structural features of the triazole scaffold through docking calculations 
on the basis of a structure-based analysis was reported.91 Moreover, was 
achieved the identification of four synthetic lead compounds from a small 
library by molecular docking, three of them showed also 5-LOX inhibitory 
activity. Two of them, acting as weak inhibitors, were further optimized to 
develop new possible mPGES-1 inhibitors. Finally in this chapter, by means of 
a structure-based drug design strategy, from a series of novel biphenylic 
derivatives two potent inhibitors were indentified. 
The chapter 4 is related to the theoretical and biological evaluation of natural 
molecular platforms targeting mPGES-1 and/or acting as dual inhibitors of 
mPGES-1/5-LOX. As first step, we reported the virtual screening of a focused 
library of natural bioactive compounds by means of molecular docking as 
potential mPGES-1 inhibitors and the in vitro assay of the selected compounds. 
Afterwards, the in vivo and in vitro biological evaluation of anti-inflammatory 
response of carnosol and carnosic acid and in silico analysis of their mechanism 
of action were studied. The biological effects are mainly due to the inhibitory 
activity on arachidonic related metabolites production, these effects might 
contribute for the anti-nociceptive, anti-inflammatory and antitumoral property 





computational analysis. Another study has concerned the molecular 
mechanism of tanshinone IIA and cryptotanshinone in platelet anti-aggregating 
effects.92 Until now, the molecular mechanisms of action of these two 
diterpenoids on platelets are partially known. To clarify this aspect, here we 
utilized an integrated study of pharmacology and computational analysis 
determinating that they are able to inhibit in a concentration dependent manner 
the rat platelet aggregation and act as antagonist of Gi-coupled P2Y12R. 
In the chapter 5, the relative configurations of the giffonins J-P93 were 
assigned by a combined QM/NMR approach, comparing the experimental 
13C/1H-NMR chemical shift data and the related predicted values.  
Finally, after a brief conclusions of our studies, the adopted computational 
techniques, the employed biological evaluation, assay systems and the use of 
quantum mechanical calculation of the NMR parameters (e.g. chemical shifts) 







































Determination of new synthetic molecular 
























3.1 Determination of new synthetic molecular platforms as 
mPGES-1 inhibitors: structure-based drug discovery 
mPGES-1 has emerged as an attractive target for the discovery and 
development of new anti-inflammatory and anti-cancer drugs. Interestingly, no 
selective inhibitors targeting mPGES-1 have been identified and, despite the 
high number of published patents, only one of these drugs has yet made it to 
the clinic. In this framework, the first X-ray crystal structure of human mPGES-
1 (4AL1) published by Geschwindner and co-workers72 represents a powerful 
tool for the rational in silico design of potent and efficient mPGES-1 inhibitors. 
It was crystallized in the presence of GSH in the active site of the enzyme 
defined mostly by TM1 and TM4 for each of the three subunits. GSH interacts 
in a ‘U-shape’ mainly with Arg126, Arg110 and Glu77 from TM4 and His72 
from TM1 of another subunit. A model of the open conformation reveals that 
prostaglandin endoperoxide (PGH2) could fit into the cleft defined by TM1 and 
TM4, allowing the synthesis of PGE2. Moreover, further high-resolution X-ray 
structures of human mPGES-1 have been reported in complex with several 
potent inhibitors acting both as substrate (available crystal structures with PDB 
codes: 4BPM73 4YK5, 4YL0, 4YL1, 4YL3).74 This new structural information, 
and the retrospective analysis of the mode of interaction of the already 
developed inhibitors, are useful to confirm the pharmacophoric portions of 
potential mPGES-1 blocking agents. Thus, the focus of this research is the 
identification of new synthetic and natural platforms targeting mPGES-1 as 
anti-inflammatory and anti-cancer agents. AutodockVina129 and Glide were 
chosen as the tool to conduct the computational studies. 
Therefore, we report initially the elucidation of new structural features of the 
triazole scaffold through docking calculations on the basis of a structure-based 
analysis.91 In the course of previous studies, we identified a novel class of 1,4-
disubstitued 1,2,3-triazoles that inhibited mPGES-1 in a cell-free assay with 
IC50 values in the low mM range.





considerations, we have undertaken a new structure drug design with the aim 
of investigating the influence of the ring-substituent topological position and 
simplifying the mPGES-1 inhibitor structure. The reported results led to the 
identification of compound 24 that showed efficient inhibitory activity and has 
proved the importance of halogen bonding as new key interaction useful for the 
design of this novel triazole derivatives as mPGES-1 inhibitors.91  
Moreover, we achieved the identification of four synthetic lead compounds 
from a small library by molecular docking, three of them showed also 5-LOX 
inhibitory activity. 36 and 38, acting as weak inhibitors were further optimized 
to develop new possible mPGES-1 inhibitors. In this way, a series of available 
building blocks to decorate the selected scaffolds were determined to render 
the ligand more affine and selective for the active pocket. The design of these 
potential new scaffolds was carried out in silico by virtual screening on the 
basis of a drug-receptor analysis, and were identified the compounds 41 and 42 
from spiro[indoline-3,2'-thiazolidine]-2,4'-dione series displaying an increase 
of the inhibitory activity (mPGES-1 inhibition of 30% and 50% respectively) 
with respect to the lead compound and the compound 43 from nitrofuran 
derivates displaying highest inhibitory activities with an IC50 of 1.37± 0.7 µM. 
Finally in this chapter, by means of a structure-based drug design strategy, 
from a series of novel biphenylic derivatives two potent inhibitors were 
indentified.74 It has guided to the identification of 2 potent inhibitors of the 
enzyme 44 and 47 showing the strongest inhibitory activity, validated with 
biological assay. These results encouraged us to start a focused SAR 
exploration to define the effect of the fluorine atom and the importance of nitro 
groups, which can influence the cytotoxicity and the pharmacokinetic 
properties. In vitro biological test of the new designed compounds show that 
the fluorine atom and nitro groups are essential for the inhibitory activity.  
Some of them have an action on other enzymes within the arachidonic acid 





the formation of leukotrienes (LTs) from arachidonic acid, is considered a 
valuable characteristic of a given mPGES-1 inhibitor, because dual suppression 
of PGE and LT formation might be superior over single interference in terms 
of higher anti-inflammatory efficacy as well as in terms of reduced side 
effects.94 
 
3.1.1. Elucidating new structural features of the triazole 
scaffold for the development of mPGES-1 inhibitors 
As confirmed by Geschwindner’s work,72 the mPGES-1 active site is sub 
divisible in cofactor (GSH) and substrate (PGH2) binding sites. Moreover, it 
includes the N-terminal (helices II and IV), the C-terminal (helix I) and an 
adjacent monomeric cytoplasmic domain. In more detail, the major portion of 
the active site is occupied by GSH while only the PGH2 ring interacts with it. 
This pattern of binding is well represented by the co-crystallized structure of 
mPGES-1 with the GSH analogue, 1-(4-phenylphenyl)-2-(S-glutathionyl)-
ethanone and a b-octyl glucoside, which discloses key interactions for the 







Figure 3.1.1.1 Three dimensional model of mPGES-1 in complex with GSH analogue and 
β-octyl glucoside depicted by violet stick and balls. The crucial amino acids of mPGES-1 
receptor are depicted by stick and balls, and ribbon colored by chains (A, red; B, green; C, light 
blue). 
 
In the course of previous studies, we identified a novel class of 1,4-
disubstitued 1,2,3-triazoles that inhibited mPGES-1 in a cell-free assay with 
IC50 values in the low mM range.
95 In particular, compound 4 (Figure 3.2) 
showed the most promising activity with an IC50 of 0.7 mM in the microsomal 
fraction of A549 cells that was used as a source for the human mPGES-1 
enzyme.96 These active compounds were disclosed by means of structure-based 
studies using the microsomal glutathione transferase 1 (MGST-1) as the model 
enzyme.97,98,99,100,101,102,103,104 Thanks to the 4AL1 human mPGES-1 X-ray 
structure resolution and studies, we have used Glide software (version 9.6)105 
with extraprecision (XP) mode, and we have designed the triazole compounds 
for an optimal placement in the substrate's binding site. On this basis, we 





3.1.1). As shown by Geschwindner, a competitive inhibitor of mPGES-1 
should be able to interact with Ile32 and Tyr28 of chain B, and Gln134 and 
Tyr130 of chain A in groove A, as well as with the cofactor, with Arg126, 
Ser127 of chain A, and with Asp49, His53, Arg38, Phe144 of chain B in groove 
B (Figure3.1.1). The best binding modes of compounds 1–5 are in agreement 









Based on these considerations, we have undertaken a new structure drug 
design with the aim of investigating the influence of the ring-substituent 
topological position and simplifying the mPGES-1 inhibitor structure. In fact, 
as can be seen from the 2D diagram interactions (Figure3.1.2), in our previous 
triazole inhibitors, the key features were represented by a benzyl group at the 
N1 position bearing a para hydrogen bond acceptor able to interact with groove 
B, responsible for PGH2 recognition and involved in its isomerisation into 
PGE2; and bis-aryl substituents at the C4 position, which establish hydrophobic 
and π–π interactions with groove A. Interestingly, in the crystallized model of 
the GSH analogue (Figure3.1) only the first aromatic ring of the biphenyl 
portion directly bonded at position 4 is involved in π–π interactions with the 
key amino acid Tyr130 (A), while the second aromatic ring is involved in 
hydrophobic interactions with groove A (e.g. Gln134 (A) and Tyr 117 (A)). 
 Based on this, we present herein the effect of the substituents inversion on 
the triazole ring. Thus, a phenyl ring was positioned on N1, while a phenoxy-
methyl group was attached at the C4 position (scaffold II, Figure 3.1.3). 
Moreover, as an effort to improve the activity with respect to the previous 
molecules, we also explored the substitution at position C5 (R7, Figure3.1.3 
and 3.1.4). The first step towards the scaffold optimization was the introduction 
of a p-substituent on ring B (II, Figure3.1.3). Docking studies performed on 
compounds 6–8 revealed that none of them was able to interact with groove B. 
Therefore, in order to improve the interaction with its amino acids (e.g. Ser127 
and Arg126), we introduced another hydrogen bond acceptor, namely a CF3 
group, at R3 of ring B (scaffold II, Figure3.1.3), in analogy to the ring B of 






Figure 3.1.1.3Scaffold hopping of the triazole pharmacophore. (A) Scaffold I, compounds 
1–5. (B) Scaffold II, compounds 6–33. 
 
 






Docking studies on derivatives 9–11 showed that, with respect to 10 and 11, 
scaffold 9 strongly interacts with groove B, being able to simultaneously 
interact with Arg126 (A), Arg38 (B), Asp49 (B) and Ser127 (A) (Figure 3.1.5), 
thus 9 was selected for further optimization. By superimposing the binding 
mode of 9 with respect to the lead compound 4 in the mPGES-1 structure, the 
para and meta positions of ring A (II, Figure3.1.3) were identified as the most 
suitable and attractive for modifications. For this reason, compound 9 was 
functionalized with four different hydrogen bond acceptors (e.g. CF3, NO2, OH 
and CN) at meta and para positions, respectively (Figure3.1.4, compounds 12–
19). From the analysis of the docking results (Figure3.1.6), the best 
substitutions were represented by the CF3 group at meta and para positions (12, 
predicted energy of binding = -7.4 kcal mol-1 and 16, predicted energy of 
binding = -7.2 kcal mol-1), and by the CN group at the para position (17, 
predicted energy of binding = -6.4 kcal mol-1), displaying an energy gain of ca. 
1.5 kcal mol-1 in comparison to those of the other complexes.  
 








Figure 3.1.1.6Superimposition of 12 (light green), 13 (purple), 14 (white), and 15 (brown) 
(panel A), and 16 (light blue), 17 (cyan), 18 (magenta), and 19 (dark green) (panel B) in the 
mPGES-1 binding site. 
 
In order to further extend the compounds’ virtual library, we inserted a 
chimeric substituent at N1 of the triazole scaffold with CF3 at meta and a CN 





a calculated binding energy of 7.6 kcal mol-1. Moreover, the analysis of the 
binding mode of 20 (Figure3.1.7) suggested that a substituent at position C5 of 
the triazole ring should protrude towards a left hydrophobic side (Ile32, Ala31 
chain B) and a right side where the polar amino acids Thr131 and Ser127 of 
chain A are located. As a consequence, we explored the effect on the binding 
energy of properly selected substitutions at this position (compounds 21–27, 
Figure3.1.4). As a result of the docking studies, derivative 24, which bears an 
iodine atom at C5, displayed the most promising binding mode (Figure3.1.8). 
 
 








Figure 3.1.1.8Three dimensional model of 24 (blue sticks) in the mPGES-1 binding site. 
 
In more detail, the portions at C1 and C4 of the triazole ring maintained 
similar binding modes of 20 (Figure3.1.8), while the iodine atom at C5 is 
involved in a halogen bond with CO of Ala31 (B). These optimal interactions 
were associated with a calculated binding energy of 8.8 kcal mol-1 for 24, which 
was in good agreement with the calculated affinities of our lead compound 15 
(Figure3.1.2). Moreover, the iodine atom at position C5 presents several 
advantages with respect to the other halogens especially in terms of halogen 
bonding strength, which decreases from iodine to chlorine. In summary, our 
docking studies suggested that this revisited version of triazole based inhibitors 
should be able to interact with mPGES-1 in the same manner of the previously 
reported 2, 4 and 5 inhibitors, and that the halogen atom should play a 







Figure 3.1.1.9Superimposition of 24 (blue sticks) with LVJ (light violet) (panel B) in the 
mPGES-1 binding site. 
 
To prove our hypothesis, starting from compound 20, we have synthesized 
compounds 16, 20 and 24. Moreover, starting from scaffold 20, to prove the 
influence of topology of selected hydrogen bond acceptors on ring B (NO2 and 
CF3 group), we have designed another small pool of compounds (28–33), and 
synthesized among them the most significant compounds (29 and 30). The 
biological evaluation of the representative compounds (16, 20, 24, 29, and 30) 





activity for 24 (IC50= 0.7± 0.2 mM) (Figure3.1.10) and significant but 
incomplete suppression of mPGES-1 activity by the other compounds (20% 
inhibition at 10 mM, IC50> 30 mM).  
 
 
Figure 3.1.1.10 Inhibition of mPGES-1 activity by compound 24 in a cell-free assay. Data 
are means ± S.E.M., n = 3. 
 
To further corroborate the influence of an iodine atom at C5 on a triazole 
scaffold on the biological activity, we have compared the putative binding 
mode of 24 with respect to the known inhibitor LVJ recently co-crystallized 
with the mPGES-1 enzyme by Caffrey and co-workers(4BPM).73 Figure 3.9 
clearly shows the good superimposition of the aromatic ring B of 24 with 
respect to the bischlorophenyl ring of LVJ in groove B of the mPGES-1 
surface, even if a more potent inhibitor (2.4 nM) makes an optimal π–π stacking 
with Phe44. On the other hand, peculiar interactions of the benzimidazole 
portion of LVJ with Ile132, Val128, Ala123, and Arg52 are partially balanced 
by the halogen bonding of 24 with Ala31, and by the contacts with Tyr28, 
Gln134 accounting for the minor inhibitory potency of 24 with respect to LVJ. 
Even if 24 shows a relatively simple skeleton in comparison to LVJ, the 





with mPGES-1 are sufficient to support its biological activity in occupying and 
inhibiting the enzyme binding site. In conclusion, thanks to the recent 
disclosure of the mPGES-1 X-ray crystal structure, we were able to perform a 
structure-based design of a novel class of potential mPGES-1 triazole 
inhibitors. In particular, compound 24 was identified as the most promising of 
the series, enabling the interaction with the membrane protein and occupying 
the PGH2 binding site, and inhibiting mPGES-1 activity in a cell-free assay 
with IC50= 0.7 mM. The smaller dimension and different interactions of the 
rings A and B with respect to the lead compound (4) are balanced by the 
presence of an iodine atom at position C5 and of precise positions of the 
substituents on these two rings. In fact, the halogen bonding of the iodine atom 
with the receptor backbone resulted as a new key interaction suitable for the 
design of new mPGES-1 inhibitors, proved by the complete inactivity of 
compounds lacking this atom.91 
 
3.1.2. Evaluation of a small synthetic library acting as 
mPGES-1 inhibitors 
The computational study on this small synthetic library was structured in 
two main tasks: identification of new compounds showing activity against 
mPGES-1, and the progressive optimization of the indentified lead compounds 
(36-38) with improved potency and, eventually, improved efficacy. In the first 
task, the identification of leads was carried out by virtual screening of a small 
synthetic library. We performed the molecular docking of the potential 
candidates using Autodock Vina129 in presence or absence of GSH, taking into 
account the possibilities that the potential inhibitor would displace the substrate 
PGH2 or it would compete with GSH for the binding. The 150 compounds were 
selected by affinity average (-10.1< ΔG< -9.5 kcal/mol) and by crucial 
interactions. In more details, the interaction with Ile32 and Tyr28 of chain B, 





with Arg126, Ser127 of chain A, and with Asp49, His53, Arg38, Phe144 of 
chain B in groove B were considered essential for the inhibitory activity. This 
step allows to select candidates with an high docking score and a rational 
binding mode. Previous studies have demonstrated that the hydrogen bond 
between inhibitor and Ser127 or His53 or Thr131 was necessary for mPGES-1 
inhibitory activity which was consistent with our analysis. Both van der Waals 
and electrostatic components play key roles in the binding. In particular the 
analysis of docking results (Figure 3.1.2.1) led us to choose seven compounds 
(34-40), which are shown in the Figure 3.1.1.2.  
 
Figure 3.1.2.1 Three-dimensional model of the interactions between 36 and mPGES-1 in 
absence of GSH (A) and in presence of GSH (B). The protein is depicted by ribbons and tube. 












The hits selected via virtual screening were then validated using an in vitro 
mPGES-1activity assay. The inhibition of mPGES-1 activity by the test 
compounds was assessed in cell-free assays using overexpressed mPGES-1 in 
microsomal preparations of interleukin-1b-stimulated A549 cells.106 In 
particular, the determination of product formation by mPGES-1 demonstrated 
that the compounds 34-38 exhibited weak inhibitory activity (Figure 3.1.2.3). 
Analysis of the inhibition of mPGES-1 activity (i.e., the transformation of 
PGH2 to PGE2) by a given compound in the cell is not immediately feasible, 
since other enzymes than mPGES-1 are involved in PGE2 formation in 
stimulated cells (i.e. COX-1/2, cPGES and mPGES-2), and an appropriate test 
system is not available. The mPGES-1 inhibitor MK-886 (3-(3-(tert-butylthio)-
1-(4- chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid), 
was used as reference compound. 
 
Figure 3.1.2.3 Effect of the selected compounds on mPGES-1 activity. Data are given as 
means ± SE, n = 3. 
 
A promising approach to enhance the efficacy is offered by targeting with a 
single agent more than one component of the inflammatory cascade. 
Furthermore, in order to find dual inhibitor of mPGES-1/5-LOX or to 
investigate the selectivity profile, the selected compounds were also tested 


































against 5-LOX enzyme. The inhibition of 5-LOX activity by the test 
compounds was assessed in cell-based assays using ionophore A23187-
stimulated human polymorphonuclear leukocytes (PMNL) in the presence of 
exogenous AA (20 mM) as 5-LOX substrate.107 
 
Figure 3.1.2.4 Effect of selected compounds on 5-LOX activity. Data are given as means 
± SD, n = 3. 
 
5-LOX activity was suppressed by 34-35 and 37 in intact cells (Figure 
3.1.2.4). Of interest, the compounds 35-37 showed the lower IC50 values of 
3.76± 1.2 and 3.63± 0.9 µM µM respectively (Figure 3.1.2.5), which have good 






Figure 3.1.2.5 Concentration-response curves of compounds 35 (A) and 37 (B) for 
inhibition of 5-LOX activity. Data are given as means ± SD, n = 3.  
 
Note that in intact PMNL a given test compound may suppress 5-LOX 
product synthesis without inhibiting 5-LOX directly, for example by 
modulating cellular co-factors of 5-LOX or by targeting other enzymes 
involved in LT synthesis (e.g., FLAP, LTA4H, LTC4S). The 5-LOX inhibitor 
BWA4C ((E)-N-hydroxy-N-(3-(3- phenoxyphenyl)-allyl)acetamide) was used 
as control). Considering the frequent co-expression of these two enzymes and 
the striking analogy of their biological functions, dual inhibitors of mPGES-1 
and 5-LOX may present a superior anticancer profile in carcinogenesis. And 
notably, there is a cross-talk between mPGES-1 and 5-LOX pathways, 
inhibition of only one of them would shunt AA metabolism to the other 
pathway, thereby inducing potential side effects. Hence the dual mPGES-1/5-
LOX inhibitors would be safer under the anti-inflammatory profile.  
The reported weak inhibitors represent promising starting points for further 
medicinal chemistry optimization. Therefore, we are confident that we can 
design and optimize the leads based on the predicted binding mode to improve 
the potency. 
 
3.1.3. Optimization of 36-38 derivates as mPGES-1 
inhibitors 
Continuing the studies described in the previous paragraph, some interesting 
molecules able to inhibit mPGES-1 as well as other key enzymes of the 
arachidonic acid cascade such as 5-lipoxygenase (5-LOX) were identified. The 
good accordance between the biological results and the predictions of 
molecular docking calculations for the compound 36 and 38 has prompted us 
to develop some derivatives of these two compounds.The identification of the 





optimized compounds, able to bind the protein with higher affinity with respect 
to the parent compound covering further regions thanks to the additional 
chemical groups. In more detail, the previous investigations have disclosed 36 
and 38 able to efficiently interact with key aminoacid residues in the catalytic 
site. 
Furthermore, the crystal structures of mPGES-1 reveals the standard 
requirements and key features needed for the enzyme inhibition. Firstly, a 
binding groove is between the GSH binding site and a molecular surface nearby 
the cytoplasmic part of the protein, mainly composed by aromatic (B:Phe44, 
B:His53) and polar (B:Arg52) residues. A potential ligand could establish π-
πcontacts with these aromatic groups, as occurred for the co-crystallized LVJ 
inhibitor. Moreover, Ser127 on chain A represents another fundamental 
residue, since it was supposed to be involved in the catalytic process behind 
the isomerization of PGH2 to PGE2. Finally, moving from the external part of 
endoplasmic reticulum membrane to the cytoplasmic part of the protein, an 
external binding groove is identifiable at the intersection between helix 1 of 
chain B and helix 4 of chain A, with polar (A:Gln134), aliphatic (B:Val24) and 
aromatic (B:Tyr28) residues, and could be bound by long molecular functions. 
Considering the structural requirements for mPGES-1 inhibition, we initially 
aimed at identifying a potential moiety that can interact with catalytic site and 
additional substituents to capture such polar and hydrophobic interactions with 
the external or the upper groove. In line with these considerations, it was 
decided to leave the spiro[indoline-3,2'-thiazolidine]-2,4'-dione and the 
nitrofuran moieties unchanged and to variously decorate the right hand portion 
of the molecule(Figure 3.1.3.2).  
Initially we just designed a small pool of 3'-(2-(piperazin-1-
yl)ethyl)spiro[indoline-3,2'-thiazolidine]-2,4'-dione derivates through the 
introduction of 10 acyl halides in R1, 2 alkylic halides in R2 and the reduction 





substituents in that position and of the length of the linker with respect to the 
compound 36 (Figure 3.1.3.1). 
 
 
Figure 3.1.3.1 Scaffold structures of 36 with attachment points. 
 
After an accurate design regarding the compound 36 taking into account the 
spiro[indoline-3,2'-thiazolidine]-2,4'-dione scaffold, we designed two series of 
compounds: the design of the NH spiro[indoline-3,2'-thiazolidine]-2,4'-dione 
series was done through the introduction of 80 acyl halides in R1; moreover the 
design of the NR spiro[indoline-3,2'-thiazolidine]-2,4'-dione series was done 
through the introduction of 80 acyl halides in R1 in all possible combination 
with 12 acyl halides in R2. In both, the substitution of the carbonyl group with 
ester and alcohol groups and the elongation of chain linker by 3 to 5 C atom 
were investigated; obtaining in total about 66000 compounds (Figure 3.1.3.2). 
For what concerns the compound 38, we also performed the design of two 
series of nitrofuran derivates: the first series was designed through the 
introduction of 68 ammines in R1 in all the possible combination with 2 acyl 
halides in R2; the second series was drawn through the reduction from nitro to 
amine group and the introduction of 48 acyl halides in R3. Moreover the 
substitution of nitrofuran with benzonitrofuran ring was explored; obtaining in 







Figure 3.1.3.2 Scaffold structures of 36 and 38 with attachment points. 
 
We performed the molecular docking of the potential candidates’ library using 
Autodock Vina147 in presence or absence of GSH. After the evaluation of the 
binding energies, these compounds were inspected to check whether they had 
interactions with the binding pocket of mPGES-1 and the external upper and 
lower grooves.The obtained results point out two different docking poses for 
these two first series as potential mPGES-1 inhibitors: the first one includes 
molecules which have some interactions with the aminoacids of the external 
upper groove as Tyr130, Thr131 and Gln134; the second family relates to 
compounds which show a deep interaction mode strictly closed to the GSH and 
establish interactions with lower groove like Arg52, His53 and Phe44. 





situated in the region at the interface of the two mPGES-1 subunits interacting 
with the fundamental residues, which guarantee, at least in theory, the mPGES-
1 binding (Figure 3.1.3.3). We also investigated the effects of the length of the 
linker's chain and the effect of the ketone, alcohol or ester groups, identifying 
3 atom's linker and ketone group as energetically favourite for the mPGES-1 
activity. 
 
Figure 3.1.3.3 Three-dimensional model of the interactions between 41 and mPGES-1 in 
absence of GSH. The protein is depicted by ribbons and tube. 41 is represented by sticks 
(yellow). 
 
We identified two promising candidates by the optimization of compounds 
36 (41 and 42 Figure 3.1.3.4) and one by the optimization of compounds 38 
(43Figure 3.1.3.5) as mPGES-1 inhibitor after selection by affinity average and 










Figure 3.1.3.5 Chemical structures of the selected compound 43. 
This theoretical result can qualitatively explain the biological interaction 
with the target confirmed by potent inhibitory activity. The predicted activity 
values are in good agreement with the experimental data. Herein we report the 
screening results of mPGES-1 inhibitory activity in vitro of the two synthesized 
compounds of the spiro[indoline-3,2'-thiazolidine]-2,4'-dione series. The two 
compounds 41 and 42displayed an increase of the inhibitory activity (mPGES-
1 inhibition of 30% and 50% respectively) with respect to the lead compound 







Figure 3.1.3.6 Effect of selected compounds on mPGES-1 activity. Data are given as 
means ± SD, n = 3. 
 
The inhibition curve (plot of the inhibition rate vs the concentration) for 
selected compound 43 of the nitrofuran derivates is illustrated in Figure 3.1.3.7. 
 
Figure 3.1.3.7 Concentration-response curves of compounds 43 for inhibition of mPGES-
1 activity. Data are given as means ± SD, n = 3. 
 
The compound 43 displayed highest inhibitory activities with an IC50 of 
1.37± 0.7 µM (Figure 3.1.3.8). 
The inhibition of 5-LOX activity by the test compounds in cell-based assays 
using ionophore A23187-stimulated human polymorphonuclear leukocytes 







3.1.4. Structure-based rational drug design for the 
development of new potent mPGES-1 inhibitors 
To find a specific inhibitor against mPGES-1, a series of novel biphenylic 
derivatives has been successfully designed by means of a structure-based drug 
design strategy. According to co-crystal structural data, mPGES-1 inhibitors 
interact with transmembrane helix 4 from one monomer and transmembrane 
helix 1 from the other monomer, place their head groups or cores in a groove 
above the GSH cofactor and let the hydrophobic tails protrude from the active 
site cavity. 
Hence, based on the fundamental interactions that an inhibitor have to 
establish in the receptor counterpart and on the hypothesized mechanism of 
action for the cleavage of the PGH2 peroxide bond, we have designed five 
biphenylic derivatives reported in Figure 3.4.2.1. Docking was performed 
using Autodock Vina147 in presence of the cofactor GSH, due to the hypothesis 






Figure 3.1.4.1 Chemical structures of the designed compounds. 
 
Exploring the best docking poses, the analysis revealed optimal occupancy 
of substrate binding cavity, high binding energy scores and complete 
interaction with the fundamental active site aminoacids like the co-crystallized 
inhibitors. In this case, for the accurate analysis were observed the following 
interactions: π-π interaction with Phe44, and/or His53, and/or Tyr130 and polar 
contacts with Arg38, Arg126, Ser127, and/or GSH. As additional interactions 
were noticed the hydrogen bonds with Ser127, and/or Thr131, and/or His53 the 
salt bridges with the side chain of Arg52 and some hydrophobic interactions 







Figure 3.1.4.2 Three-dimensional model of the interactions between 44 and mPGES-1. The 
protein is depicted by ribbons and tube. 44 is represented by sticks (green).  
 
The synthesized compounds were initially tested for mPGES-1 inhibition at 
1 and 10 µM concentration (Figure 3.1.4.3). 
 
Figure 3.1.4.3 Effect of designed compounds on mPGES-1 activity. Data are given as 





The percentage of inhibition confirmed our theoretical results and we also 
tested them at 3-0.1- 0.3- 0.03 µM concentration, the compounds 44 and 47 
showed the strongest inhibitory activity. 44 and 47 show a value of IC50 = 0.26± 
0.05 and 0.18± = 0.03 µM respectively, higher inhibitions than known inhibitor 
MK-886 (Figure 3.1.4.4).  
 
 
Figure 3.1.4.4 Concentration-response curves of compounds 44 (A) and 47 (B) for 
inhibition of mPGES-1 activity. Data are given as means ± SD, n = 3.  
 
The enzymatic results suggest that the substituents on the phenoxyl portion 
of the hit compounds can significantly influence the inhibitory activity, the 
substitution of the 2-trifluoromethyl phenoxy group with 2-naphthol group 
exhibit an enhancement of the inhibitory activities.  
These results encouraged us to initiate a more focused SAR exploration to 
define the effect of the fluorine atom as pharmacophoric group and the 
importance of nitro groups, due to the fact that nitro groups can influence the 
cytotoxicity and the pharmacokinetic effects. Initially, we removed the fluorine 
atom, then we replaced 4-nitro group with trifluoromethyl group to have the 
first two derivates 49 and 51. We explored the scaffold also replacing 4-nitro 
group with idroxyl group and 2-nitro group with methyl group obtaining 50. 
At the last we replaced the 4-nitro groups of 50 with amino group obtaining 52 








Figure 3.1.4.5 Chemical structures of the new designed compound. 
 
The new synthesized compounds were tested for mPGES-1 inhibition at 1 
and 10 µM concentration, in vitro biological test shows the lack of the 
inhibitory activity for the all new designed compounds, establishing in this way 
the importance of fluorine atom and nitro groups as essential for the binding 
with receptor counterpart (Figure 3.1.4.6). 
 
Figure 3.1.4.6 Effect of new designed compounds on mPGES-1 activity. Data are given as 





The inhibition of 5-LOX activity by the test compounds in cell-based assays 
using ionophore A23187-stimulated human polymorphonuclear leukocytes 





















































Determination of natural molecular platforms 























4.1. Determination of natural molecular platforms as 
mPGES-1 inhibitors 
On the basis of known natural compound reported in literature as mPGES-
1 inhibitor: curcumin from turmeric (IC50 = 0.22 μM), epi-gallocatechin gallate 
from green tea (IC50 = 1.8 μM), garcinol from the fruit rind of Guttiferae 
species (IC50 = 0.3 μM), myrtucommulone from myrtle (IC50 = 1 μM), arzanol 
from Helichrysum italicum (IC50 = 0.4 μM), boswellic acids from frankincense 
(IC50 = 3–10 μM);
79 here we report the determination of natural molecular 
platforms targeting mPGES-1. 
We reported the virtual screening of a focused library of natural bioactive 
compounds by means of molecular docking in order to identify new potential 
mPGES-1 inhibitors. From the in vitro assay of the selected compounds, the 
12-O-methylsalvipalestinoic acid shows significantly inhibitory mPGES-1 
activity. This molecule causes dual suppression of PGE2 and LT formation 
might be superior over single interference in terms of higher anti-inflammatory 
efficacy as well as in terms of reduced side effects, the compounds were then 
tested for inhibition of 5-LOX activity in a cell-based assay using PMNL. As 
first step, we performed an accurate conformational search at empirical level, 
combining with Monte Carlo Molecular Mechanics (MCMM) and Molecular 
Dynamics (MD) simulations to explore the conformational space. 
Another line of this project has regarded the in vivo and in vitro biological 
evaluation of anti-inflammatory response of carnosol and carnosic acid and in 
silico analysis of their mechanism of action. We investigated the effects of 
these compounds in different models of inflammatory pain. The compounds 
displayed at 4h a significant and dose-dependent anti-inflammatory and anti-
nociceptive effects in carrageenan-induced hyperalgesia in mice and also 
inhibited the late phase of formalin test. The biological effects showed 
significant inhibitory activity on arachidonic related metabolites, these effects 





property of others Salvia spp. containing these diterpenoids. In conclusion, our 
molecular docking and biological studies have allowed the rationalization of 
the antinociceptive and anti-inflammatory effects of carnosol and carnosic acid 
associated to the inflammatory pain, which are related to the biological activity 
on some key enzymes involved in the arachidonic acid cascade such as 
mPGES-1, 5-LOX, COX-1 and COX-2. In fact, the multiple suppression might 
be superior over single inhibition in terms of efficacy as well as in terms of side 
effects. 
Another study has concerned the molecular mechanism of tanshinone IIA 
and cryptotanshinone in platelet anti-aggregating effects. Until now, the 
molecular mechanisms of action of these two diterpenoids on platelets are 
partially known. To clarify this aspect, here we utilized an integrated study of 
pharmacology and computational analysis. Cryptotanshinone is able to inhibit 
in a concentration dependent manner the rat platelet aggregation and also is 
endowed of Gi-coupled P2Y12 receptor antagonist as demonstrated by docking 
studies. This computational method was also performed for tanshinone IIA 
demonstrating even for this diterpenoid an interaction with the same receptor. 
The findings from our study enable a better understanding of TIIA and CRY 
biological properties, which could ultimately lead to the development of novel 
pharmaceutical strategies for the treatment and/or prevention of some 
cardiovascular disease.92 
 
4.1.2. Virtual screening of focused library, pilot study on 
natural bioactive compounds by means of molecular docking 
Numerous natural products from plants with anti-inflammatory properties 
have long been recognized as efficient repressors of PGE2 biosynthesis in intact 
cells. Detailed analysis of their molecular targets and modes of action revealed 
mPGES-1 as primary point of attack providing unique chemotypes for 





products include lipophilic acidic molecules including: cylphloroglucinols 
such as myrtucommulone A, hyperforin, arzanol; (poly)phenols such as 
epigallocatechin-3-gallate, curcumin, the depside perlatolic acid and the 
depsidone physodic acid; quinones such as embelin, and tetra- or pentatcyclic 
triterpene acids such as boswellic, tirucallic and lupeolic acids.83 The IC50 
values of most of these natural products for mPGES-1 are in the range of 0.2 
to 10 µM,83 and some of them have been demonstrated to suppress PGE2 levels 
in vivo, connected to anti-inflammatory activity. Inhibition of mPGES-1 by 
these natural products may rationalize the anti-inflammatory properties of 
remedies containing them, and they may also serve as novel templates for drug 
development. 
Our natural small library with approximately 80 compounds was screened 
through molecular docking and binding free energy evaluation. Initially, we 
performed an accurate conformational search at empirical level, combining 
with Monte Carlo Molecular Mechanics (MCMM) and Molecular Dynamics 
(MD)177 simulations. The library were then docked by Autodock Vina129 
software, subsequently the compounds were selected using a binding score 
range, defined between −9.9 and 8.6 kcal/mol as cut-off, and the key 
interactions, as reported above (Figure 4.1.2.2). From this analysis, 8 













Figure 4.1.2.2 Three-dimensional model of the interactions between 56 and mPGES-1 in 
absence of GSH (A) and in presence of GSH (B). The protein is depicted by ribbons and tube. 
56 is represented by sticks (yellow). GSH is represented by sticks (red). 
 
To assess the ability of the selected compounds to interfere with the activity 
of mPGES-1, a cell-free assay using the microsomal fractions of interleukin-
1β (IL-1β)-stimulated A549 cells (as source for mPGES-1) was applied (Figure 
4.1.2.3). All compounds, solubilized in dimethyl sulfoxide (DMSO), were 
tested at concentrations of 1 and 10 μM. The mPGES-1 inhibitor compound 
MK886 (IC50 = 2.4 μM) was used as a reference control, and DMSO (0.3%, 






Figure 4.1.1.3 Effect of selected compounds on 5-LO activity. Data are given as means ± 
SD, n = 3. 
 
12-O-methylsalvipalestinoic acid significantly inhibited mPGES-1 activity, 
whereas all other molecules were not significantly active. Interestingly, these 
data confirm the results from the docking studies favouring that compounds as 
mPGES-1 inhibitors. 
Previous studies on acid mPGES-1 inhibitors showed that such compounds 
often interact also with other enzymes within the arachidonic acid cascade, 
such as 5-LOX or FLAP. In fact, interference with 5-LOX or FLAP, the key 
enzymes in the formation of leukotrienes (LTs) from arachidonic acid, is 
considered a valuable characteristic of a given mPGES-1 inhibitor, because 
dual suppression of PGE2 and LT formation might be superior over single 
interference in terms of higher anti-inflammatory efficacy as well as in terms 
of reduced side effects. Thus, we further analyzed the test compounds (1- 10 
μM, each) for inhibition of 5-LO activity in a cell-based assay using PMNL as 
the intact cell enzyme source. The well recognized 5-LO inhibitor BWA4C 
((E)-N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide) was used as a 









































positive control, and DMSO (0.3%, v/v) was used as a vehicle control. The 
molecules were not significantly active (Figure 4.1.2.4). 
 
Figure 4.1.1.4 Effect of selected compounds on 5-LO activity. Data are given as means ± 
SD, n = 3. 
 
4.1.2. In vivo and in vitro biological evaluation of anti-
inflammatory response of carnosol and carnosic acid and in 
silico analysis of their mechanism of action 
Diterpenoids are secondary metabolites that can be found in higher plants, 
fungi, insects and marine organisms and display a great deal of biological 
activities.108,109 The anti-inflammatory characteristics of some members of 
diterpenoid family, especially those isolated from plants, have been described 
and mostly involve the multiple signaling pathways that are deregulated during 
inflammation and inflammatory pain syndrome, including nuclear factor κB, 
p38 mitogen-activated protein kinase and phosphatidylinositol-3-kinase. 
Among these, much attention has been recently pointed on the diphenolic 
diterpenoids carnosol and carnosic acid. Recent investigations have 
demonstrated that these compounds are able to suppress COX-2, IL-1β and 





regulate the levels of inflammatory chemokines MMP-9 and MCP-1 on cell 
migration.111 It has been found that Salvia spp. (Lamiaceae) that contain these 
diterpenoids, could act as a mild analgesic. Recent investigations have 
demonstrated the anti-nociceptive potential of Salvia officinalis extract and its 
isolated compounds carnosol in different in vivo models of inflammation. 
Subsequently it has been validated that the hydroalcoholic extract of Salvia 
officinalis and its constituent carnosol inhibit formalin-induced pain and 
inflammation in mice.112 One of the most recent specie of Salvia that has 
attracting the attention of the researchers for its high content of carnosic acid 
is represented by Salvia solamensis Vatke113. In light of the ethno botanical use 
of Salvia species, in which the main constituents are diterpenoids, in the 
treatment of pain and inflammation, here we have evaluated the potential 
analgesic activity of diphenolic terpenes carnosol and carnosic acid using in 
vivo models of inflammatory and mechanical pain. Since unsufficient data are 
reported on the antinociceptive effects of mentioned compounds, we have also 
expanded previous observations taking on account the possibility to investigate 
their potential arachidonic enzyme related inhibitory activity (cicloxygenase 1 
and 2 COXs, microsomal prostaglandin E synthase-1 mPGES-1, and 5-
lipoxygenase 5-LOX) by molecular docking studies and biological assay.  
 
 






Finally, we have evaluated, by molecular docking, the interaction of 
carnosol and carnosic acid with mPGES-1, 5-LOX, COX-1 and COX-2 
enzymes in order to understand at the molecular level the analgesic action 
related to the inflammatory pain of these two compounds. In particular, 
carnosol and carnosic acid are accommodated in the pocket situated in the 
region at the interface of the two mPGES-1 subunits,72 establishing good 
interactions with receptor counterpart. Carnosol respects the fundamental 
hydrophobic, electrostatic and π-π interactions namely with Arg38, Phe44, 
Arg52, His53 of the chain A, and Arg126, Pro124, Ser127, Thr131of the chain 
B (Figure 4.1.2.4), in analogy to the co-crystallized ligand. Moreover, it makes 
other interactions with Gly35, Leu39, Asp49 of the chain A, and Ala123, 
Val128 of the chain B (Figure 4.1.2.4), and it establishes a hydrogen bonds 
with the side chain of Arg52 (Figure 4.1.2.4). On the other hand, carnosic acid 
shows the same pattern of hydrophobic, electrostatic and π-π interactions and 
it establishes an extra hydrogen bond between hydroxyl group at position 11 





Figure 4.1.2.4 3D models of carnosol (A) (orange) and carnosic acid (B) (fuchsia) in the 
binding site of mPGES-1 with GSH (green). Residues in the active site are represented in tubes. 
2D panels represent the interactions between carnosol (C), carnosic acid (D) and the residues 
of mPGES-1 binding site. Positive charged residues are colored in violet, negative charged 
residues are colored in red, polar residues are colored in light blue, hydrophobic residues are 
colored in green. The π-π stacking interactions and H-bond (side chain) are indicated as green 
lines, and dotted pink arrows respectively. 
 
Regarding the 5-LOX enzyme,85 the induced fit docking approach was used 
to simulate and study the interactions of carnosol and carnosic acid with the 





analysis of the most representative docking poses of carnosol in the ligand 
binding site reveals a better accommodation with respect to the carnosic acid, 
it establishes key interactions with Phe177, Tyr181, Leu368, Ile406, Asn407, 
Leu414, Leu420, Phe421, His432 and Leu607 (Figure 4.1.2.5). Moreover, it is 
involved in two hydrogen bonds with Gln363 and the carbonyl oxygen 
coordinates the metal (Figure 4.1.2.5). Carnosic acid shows an opposite 
binding mode with respect to carnosol maintaining the metal coordination, a 
hydrogen bond with His372, and the key interactions with Phe177, Tyr181, 
Leu368, Ile406, Asn407, Leu414, Phe421, Leu607, with the exception of 
contacts with Leu420 and His432 (Figure 4.1.2.5). 
 
Figure 4.1.2.5 3D models of carnosol (A) (green) and carnosic acid (B) (fuchsia) in the 
binding site of 5-LOX. Residues in the active site are represented in tubes and Fe is depicted 
as yellow cpk. 2D panels represent the interactions between carnosol (C), carnosic acid (D) 
and residues of the 5-LOX binding site. Metal coordination and salt bridge are indicated as 






To evaluate the binding modes of carnosol and carnosic acid in the COX-1 
and COX-2 pockets, we have performed an induced fit docking calculation. To 
this aim, we have ascribed the biological activity of both diterpenoids to the 
carboxylate group, peculiar structural feature of classical COXs inhibitors, and 
to the lactone moiety. In particular, the carboxylate group of carnosic acid is 
involved in hydrogen bonds with Arg120 of both COXs enzymes. Moreover, 
it makes the same hydrophobic interactions in the iso-enzyme catalytic sites, 
namely with Leu93, Met113, Val116, Val349, Leu352, Tyr355, Leu359, 
Trp387, Phe518, Gly526, Ala527, Leu531, Leu357COX-1 and Phe357COX-2, 
Ile523COX-1 and Val523COX-2, and polar interactions with Ser353 and Ser530. 
Furthermore, comparing the binding modes of the carnosic acid in COXs 
ligand binding sites, the natural diterpenoid shows additional contacts with 
Leu117, Gln350 and Met522 of COX-1, and with Tyr348, Phe381, Tyr385 and 
Leu534 of COX-2 (Figure 4.2.6). For what concern the lactone moiety of 
carnosol, it is involved in the same hydrogen bonds with Arg120 of both COXs 
enzymes; moreover, it establishes the same hydrophobic and polar interactions 
with respect to carnosic acid in COX-1 binding site, except for contacts with 
Leu93, Leu117, and Leu384. In COX-2 active site, it makes further interactions 






Figure 4.1.2.6 3D models of carnosol (yellow) and carnosic acid (pink) in docking with 
COX-1 (A) and COX-2 (D). Active binding sites are representedas red (COX-1) and green 
(COX-2) molecular surfaces. 2D panels represent the interactions between carnosol (B in 
COX-1 binding site, E in COX-2 binding site) and carnosic acid (C in COX-1 binding site, F 
in COX-2 binding site).  
 
To verify the predicted binding of carnosol and carnosic acid and to 
investigate the functional consequences on mPGES-1 and 5-LOX activity, we 
determined the effect of the test compounds on the enzymatic conversion of 
PGH2 to PGE2 in a cell-free assay using microsomes of interleukin-1b-
stimulated A549 cells and on the enzymatic conversion of AA to LTB4 in cell-
free assays using partially purified human recombinant 5-LOX. In these assays, 
reduced enzymatic activity is most likely due to direct interference of the test 






Figure 4.1.2.7 Concentration-response curves of carnosol and carnosic acid for inhibition 
of mPGES-1 activity. Data are given as means ± SD, n = 3. 
 
In a cell-free mPGES-1 activity assay, carnosol and carnosic acid inhibited 
the enzymatic conversion of PGH2 to PGE2 catalyzed by mPGES-1 in 
microsomes from stimulated A549 cells106 with IC50 10.94± 2.36 and 14.0±2.95 
µM, respectively (Figure 4.1.2.7). 
 
Figure 4.1.2.8Concentration-response curves of carnosol and carnosic acid for the 
inhibition of 5-LOX activity. Data are given as means ± SD, n = 3. 
 
Moreover, they potently inhibited also 5-LOX107 with IC50 values of 0.29± 
0.03 and 0.81± 0.05 µM respectively, in cell-free system (Figure 4.1.2.8).114 
In order to investigate whether or not the test compounds also inhibit the 
enzyme inside the cell and to quantify the production of arachidonic cascade 
metabolites we performed the lipid mediator profiling in PMNL and monocytes 





preincubated with the test compounds (dissolved in DMSO) for 10 min at 37 
°C, then were stimulated with 2.5 μM Ca2+-ionophore A23187 for 15 min at 37 
°C, we stopped the reaction through the addition of 1 mL of methanol and the 
extraction of the eicosanoids were performed by SPE after the addition of 530 
µM PBS/HCl and PGB1 100 ng/ml. The analysis of all the arachidonic cascade 
metabolites  shows a significant effects on 5-LOX and COX metabolites 
production by carnosol and carnosic acid at 10 µM and 30 µM concentration, 
and on 12-LOX, 15-LOXand mPGES-1 metabolites production by carnosol 

















Figure 4.1.2.9 Effect of carnosol and carnosic acid at 3- 10- 30 µM on LTB4 (A), 
epitransLTB4 (B), 5HETE (C), 5,12-DiHETE (D), 5,15-DiHETE (E), LXA and isomers (F), 
5-oxoETE (G), 5HETrE (H), 5HETrE (I), 5HEPE (J), 8HETE (K), 9HETE (L), 12HEPE (M), 
12HETE (N), 15HETE (O), 9HODE (P), PGE2 (Q), PGE2α (R), 11HETE (S), 160-PAF (T), 







PBMC frEshly isolated from buffy coats of human blood were plated in 170 
cm2 culture flask in RPMI culture medium (RPMI 1640 containing 100 U/mL 
penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine and 2% (v/v) human 
serum) to let them adhere. After 1.5 h at 37 ˚C and 5% CO2, monocytes were 
collected by scraping of the flask and 1.5×106 /mL of monocytes were 
stimulated with LPS 10 ng/mL for 24 h in order to measure the production of 
mPGES-1 and COXs metabolites. Test compounds or vehicle were added and 
30 min before the stimulus, For measurement of eicosanoids levels 
supernatants were collected after centrifugation (2000 g, 4 8C, 10 min). Then 
extracted by SPE and analysed by UPLC-MS/MS. The analysis and the 
quantification of mPGES-1 and COXs metabolites shows significant effects on 
mPGES-1 and COXs metabolites production by carnosol and carnosic acid at 
30 µM concentration, and an intermediate inhibition on them by carnosol and 











Figure 4.1.2.10 Effect of carnosol and carnosic acid at 3- 30 µM on 12HEPE (A´), 12HETE 
(Bˊ), PGE1 (C´), PGE2α (Dˊ) PGE2 (Eˊ), 12HHT (Fˊ), 12HEPE (G´), 12HETE (Hˊ), 11HETE 
(I´), 9HODE (Jˊ), 13HODE (K´), LXA and isomers (Lˊ), TxB1 (M´), TxB2 (Nˊ), 20HDoDE 
(O´) production. Data are given as means ± SD, n = 3. 
 
These results demonstrate that carnosol and carnosic acid present a 





effects might contribute for the anti-nociceptive, anti-inflammatory and 
antitumoral property of others Salvia spp. containing these diterpenoids. In 
conclusion, our molecular docking studies have allowed the rationalization of 
the antinociceptive and anti-inflammatory effects of carnosol and carnosic acid 
associated to the inflammatory pain, which are related to the biological activity 
on some key enzymes involved in the arachidonic acid cascade such as 
mPGES-1, 5-LOX, COX-1 and COX-2. In fact, the multiple suppression might 
be superior over single inhibition in terms of efficacy as well as in terms of side 
effects. 
 
4.3 The molecular mechanism of tanshinone IIA and 
cryptotanshinone in platelet anti-aggregating effects: an 
integrated study of pharmacology and computational analysis 
Here, we utilized an integrated study of pharmacology and computational 
analysis to explain the molecular mechanism of tanshinone IIA and 
cryptotanshinone in platelet anti-aggregating effects.92 They are two 
pharmacologically active diterpenoids extracted from the roots of Salvia 
milthiorriza Bunge, a plant used in chinese traditional medicine for the 
treatment of some cardiovascular and cerebrovascular disease. Until now, the 
molecular mechanisms of action of these two diterpenoids on platelets are 
partially known. To clarify this aspect, our results demonstrate that 
cryptotanshinone is able to inhibit in a concentration dependent manner the rat 
platelet aggregation and also is endowed of Gi-coupled P2Y12 receptor 
antagonist as demonstrated by docking studies. This computational method 
was also performed for tanshinone IIA demonstrating even for this diterpenoid 
an interaction with the same receptor.  
The findings from our study enable a better understanding of tanshinone IIA 





development of novel pharmaceutical strategies for the treatment and/or 
prevention of some cardiovascular disease.  
It is well known that adenosine diphosphate (ADP) plays a key role in 
platelet activation. Aberrant activation of platelets by pathological factors is 
commonly associated with vascular disease and thrombosis.117 ADP activates 
platelets through two G-protein coupled receptors, the Gq-coupled P2Y1 
receptor and Gi-coupled P2Y12 receptor.
118These receptors are targets for 
common anti-platelets agents such as aspirin and clopidogrel.119 However, the 
chronic use of these agents is limited because they can induce resistance or 
adverse effects on gastrointestinal tract120 and, as often happens, drug toxicity 
may be increased when multiple antiplatelet drugs are used. In this context, 
new antiplatelet agents are greatly needed to increase the efficacy and reduce 
side effects. At nowadays, an increasing number of studies have been 
performed to search new agents from natural source and it is well know that 
some phytochemicals from plants have generated new drugs.121,122,123 
Tanshinone IIA (TIIA, 63 in Figure 4.1.3.1), from roots of Salvia 
milthiorriza Bunge (Lamiaceae) (also known as danshen), is an example of 
diterpenoid, studied in vitro and in vivo, able to inhibit platelet aggregation and 
to induce an increase of blood viscosity. We have previously demonstrated that 
these effects are mediated via the modulation of tubulin acetylation and 
inhibition of Erk-2 phosphorylation.124 In our continuing studies on 
pharmacology of danshen constituents, here we explored the effect of 
cryptotanshinone (CRY, 64 in Figure 4.1.3.1), another major lipophilic 






Figure 4.1.3.1 Molecular structure of tanshinone IIA (63), cryptotanshinone (64) and 
AZD1283 (65). 
 
To this aim, we have tested in vitro the potential antiaggregant effect of 64 
and simultaneously the interaction of 63 and 64 on the purinergic platelet 
receptor by a computational analysis. Tanshinone IIA (63), one of the lipophilic 
constituent present in danshen, is able to inhibit platelet aggregation and to 
induce an increase of blood viscosity via the modulation of tubulin acetylation 
and inhibition of Erk-2 phosphorilation. Here, we expand our previous 
observations and, by a molecular docking study, we investigated the interaction 
of 1 with the binding site of G-protein-coupled purinergic receptors P2Y12R 
(PDB code: 4NTJ)128 using AutodockVina software129. P2Y12R, is a target for 
the development of novel anti-platelet therapies being involved in the 
regulation of the platelet activation and thrombus formation.130,131 In particular, 
in order to rationalize the binding mode of 1, we have used the crystal structure 





l-yl)-5-cyano-2-methylnicotinate non-nucleotide antagonist (AZD1283, 65 in 
Figure 4.1.3.1)128 as model receptor for our docking studies. 
As already reported128, 65,a potent antagonists of the P2Y12, makes a 
number of polar and hydrophobic contacts in the pocket 1 with side chains of 
amino-acids of the helices III-VII, mainly interacting with Tyr105, Phe252, 
Arg256, Tyr259, Leu276 and Lys280 (Figure 4.1.3.2), and adopting a different 
orientation with respect to the agonist.132 On these basis, we have analyzed the 
binding mode of 1 in the P2Y12R in comparison with the co-crystallized 
antagonist 3. From the analysis of this docking studies, even if 63 occupies the 
pocket 1 (helices III, IV and V), in analogy to the 65, accounting for its 
antagonist activity, it poorly interacts with helices VI and VII (Figure 4.1.3.3) 
due to its smaller size compared to 65 (Figures 4.1.3.2 and 4.1.3.3). 
In more details, 63 shows polar interactions with Asn159, Asn191 and 
Arg256, and it makes hydrophobic contacts with Val102, Phe252, Arg256 and 
Lys280. Furthermore, 63 establishes a weak hydrogen bond between oxygen 
at position 11 and the side chain of Cys194, and it forms π-π interactions with 
the side chains of Tyr105, as observed for 65, and of Tyr109 (Figure 4.1.3.3). 
In our continuing studies on pharmacology of danshen constituents, here we 
also explored the effect of 64, another major lipophilic constituent present in 







Figure 4.1.3.3 3D model of tanshinone IIA (colored by blue sticks) and AZD1283 (colored 
by fuchsia sticks) in the antagonist binding site of P2Y12R (PDB code: 4NTJ). 
 
Figure 4.1.3.4 3D model of tanshinone IIA (colored by atom types: C blue, O red) into 
P2Y12R binding site. Residues in the active site (pocket 1) are represented in sticks and balls 
(colored by atom types: C gray, N blue, O red, H white, S yellow). 
 
Figure 4.1.3.4 shows a concentration-dependent inhibition of reversible 
platelet aggregation expressed as % of inhibition of AUC (Figure 4.1.3.4A) or 
amplitude (Figure 4.1.3.4B) induced by 64 (0.5, 5 and 50 µM) added 1 min 





maximum inhibitory activity in terms of inhibition of AUC (66.30±14.11%; 
P<0.01) and amplitude (31.00±7.09 %; P<0.01). 
 
Figure 4.1.3.5 Concentration dependent effect of CRY on ADP-induced platelet 
aggregation. Rat PRP were incubated with CRY (0.5-50 μM) for 1 min, and then exposed to 
ADP (3 μM) to induce platelet aggregation. Percent (%) inhibition of aggregation was 
expressed in terms of AUC (A) or amplitude (B) calculated as the difference between the 
maximum value of aggregation in presence of ADP plus vehicle and the value obtained in the 
presence of ADP plus CRY. Data are expressed as mean ± SEM. *P < 0.05 vs vehicle,**P < 
0.01 vs vehicle (one way ANOVA; n=7). 
 
Moreover, considering the structural similarity of the 64 with 63 and its 
biological activity reported above, we have performed molecular docking 
studies of 2 with the P2Y12R receptor (Figure 4.1.3.5). Cryptotanshinone 
shows the same polar interactions and hydrophobic interactions of 63 in the 





additional hydrophobic interaction with VAL190 (Figure 4.1.3.6), accounting 
for the predicted similar energy of binding. The absence of the double bond at 
position 17 in 2, in fact, does not affect its binding with P2Y12R with respect 




Figure 4.1.3.6 3D model of tanshinone IIA (colored by blue sticks), AZD1283 (colored by 
fuchsia sticks), and tanshinone II-A (colored by blue sticks) into P2Y12R binding site.  
 
 
Figure 4.1.3.7(A) 3D model of cryptotanshinone (colored by atom types: C green, O red) 
in the binding site of P2Y12R. Residues in the active site are represented in sticks and balls 





interactions between cryptotanshinone and residues in P2Y12R binding site (charged residues 
are colored in violet, polar residues are colored in light blue, and hydrophobic residues are 
colored in green). 
 
In conclusion, even if tanshinone IIA and cryptotanshinone show a 
relatively simple skeleton in comparison to the AZD1283, our docking results 
suggest that their established interactions with P2Y12R are sufficient to 
rationalize the P2Y12R antagonist activity of these two diterpenoids. The 
findings from our study enable a better understanding of 63 and 64 biological 
properties, which could ultimately lead to the development of novel 
pharmaceutical strategies for the treatment and/or prevention of some 
cardiovascular disease. 
Furthermore, the tanshinones, such as tanshinone IIA and cryptotanshinone, 
and their derivatives, in fact, could be utilizable as lead compounds for future 
cancer and anti-inflammatory active molecules,133 being able to inhibit the 
growth and proliferation of cancer cells, to induce cell cycle arrest and 
apoptosis, and to inhibit angiogenesis.  
Indeed, tanshinone IIA shows both in vitro and in vivo biological effects 
comparable to those of pan-inhibitors, such as curcumin and oridonin, and 
interestingly, it interferes with the pathway of biosynthesis of PGE2, in 
particular with the COX2 receptor.
133,134 On these bases, here we suggest the 
possible interaction of 63, in analogy with 64, with the microsomial 
prostaglandin E2 synthase (mPGES-1). The inhibition, in fact, of these two 
diterpenoids on PGE2 production by mPGES-1, could suggest a potential 
association of their anti-inflammatory and antiplatelet activity.Figure 4.3.8 
clearly shows the good superimposition of the tanshinones skeleton with 
respect to LVJ in the groove B of mPGES-1 surface, even if the more potent 





On the other hand, tanshinoneIIA (TIIA) and cryptotanshinone (CRY) make 
interactions with the key aminoacids His53, Phe44, Tyr130, and glutathione 
(GSH) accounting for a potential inhibitory activity In conclusion, our docking 
calculations suggest that the pattern of interactions established with mPGES-1 
is sufficient to suggest their biological activity in occupying the enzyme 
binding site (Figure 4.1.3.8).  
 
Figure 4.1.3.8 Superimposition of Tanshinones IIA (blue sticks, A) and cryptotanshinone 








































5.1 QM/NMR integrated approach: a valid support to the 
determination of relative configuration of unknown 
molecules 
Stereochemical features have a profound impact on a variety of molecular 
properties, such as chemical reactivity and catalytic, biological, and 
pharmacological activities. Many fundamental biological structures (protein, 
DNA, RNA), involved in cellular processes, are chiral. Drug-macromolecule 
interactions also depend on structural features of the ligand, such as 
conformation and configuration. Indeed, many bioactive compounds, involved 
in recognition process by a macromolecule, present stereocenters and often 
only one of two enantiomers can exerts its biological activity. In light of the 
above considerations, full stereochemical knowledge of a given system is of 
fundamental importance in many different fields, spanning from chemical 
physics to biochemistry. For this reasons, the assignment of the configurational 
pattern in chiral organic compounds containing more than one stereocenter is 
undoubtedly a key step of the structure elucidation process. The stereochemical 
analysis of compounds with well-defined conformational properties is 
presently fairly easy to accomplish, given the wealth of high-resolution NMR 
experiments useful in these kinds of studies. Typically, cyclic compounds with 
three to six-membered rings display a predictable conformational behaviour, 
thus allowing the knowledge of their configuration to be extracted from simple 
NMR parameters, such as proton-proton J-coupling values and/or nuclear 
Overhauser effect intensities. A much more challenging task is the assignment 
of relative (and hence absolute) configuration in the case of conformationally 
flexible systems, such as polysubstituted open chains and macrocyclic 
compounds. Quantum Mechanical (QM) methods are gaining increasing 
popularity in the structural study of medium to large sized molecules, including 





DFT calculations of NMR parameters (e.g. chemical shifts) may supply a new 
way to sort out difficult cases in the elucidation process, especially where NMR 
experimental data are difficult to interpret or can be misleading. Bifulco and 
co-workers has developed a protocol for the configurational assignment of 
organic molecules based on QM calculation of NMR properties such as 13C 
chemical shift and J coupling constants. Quantum-mechanical 13C chemical 
shift calculations methodology can be applied for the structure validation of 
natural products and for the determination of the configuration of medium 
weight low polar flexible compounds.164,165,135. In this chapter, we show the 
applicability of a combined QM/NMR approach for the determination of the 
relative configurations of seven diterpenoids through the calculation of 13C and 
1H chemical shifts (cs) and the comparison with the related experimental 
data.136 
 
5.1.1.  Giffonins J-P, Highly Hydroxylated Cyclized 
Diarylheptanoids from the Leaves of Corylus avellana, 
cultivar “Tonda di Giffoni” 
The relative configurations of giffonins J-P (66- 72) were predicted by a 
combined QM/NMR approach through the calculation of 13C and 1H chemical 
shifts (cs). The cytotoxic activities of giffonin J-P were evaluated against U2Os 
and SAOs cell lines, derived from human osteosarcomas. They exhibited EC50 
values higher than 150 μM at 24−48 h, indicating the absence of cytotoxicity 
against both cell lines. 
Corylus avellana L. (Betulaceae) is one of the most popular tree nuts on a 
worldwide basis, which may grow to 6 m high, exhibiting deciduous leaves 
that are rounded, 6–12 cm long, softly hairy on both surfaces, and with a 
double-serrate margin. The main products of C. avellana are kernels, nutritious 





consumed raw (with skin) or preferably roasted (without skin). Despite its wide 
cultivation for nuts collection, hazel leaves are also largely consumed as an 
infusion. They are used in folk medicine for the treatment of haemorrhoids, 
varicose veins, phlebitis and lower members’ oedema, as consequence of its 
astringency, vasoprotective and anti-oedema properties and also for their mild 
antimicrobial effects. Antioxidant activity was reported for hazelnuts and 
leaves of C. avellana. 
Herein, the isolation and the structural elucidation of two diaryl ether 
heptanoids (66- 67) along with five new diaryl heptanoid (68-72) are described 
(Figure 5.1.1.1). The relative configurations of giffonins J-P (66-72) have been 
established by a combined QM/NMR approach, by a comparison of the 
experimental 13C/1H-NMR chemical shift data and the related predicted values. 
Furthermore, the cytotoxic activity of giffonins J-P (66-72) and curcumin, used 
as reference compound, has been evaluated against U2Os and SAOs cell lines, 
derived from human osteosarcomas.  
Giffonins J-P structures were established by the extensive use of 1D and 
2D-NMR experiments along with ESI-MS and HR-MS analysis. The relative 
configurations of the reported compounds 66-72 were assigned by a combined 
QM/NMR approach, comparing the experimental 13C/1H-NMR chemical shift 
data and the related predicted values, as previously applied and 
reported.176,164,161 We relied on this procedure, since the chemical shifts are the 
most diagnostic parameters of the local chemical and magnetic environment 






Figure 5.1.1.1 Molecular structures of giffonins (66-72). 
 
For each considered compound, a proper sampling of the conformations was 
performed in order to attain a close agreement between calculated and 
experimental NMR parameters. For these reasons, an extensive conformational 
search at the empirical level (molecular mechanics, MM) for all the possible 
diastereoisomers of each investigated compound was carried out, combining 
Monte Carlo Molecular Mechanics (MCMM), Low-Mode Conformational 





Experimental Section). Subsequently, the selected non-redundant conformers 
were further submitted to a geometry and energy optimization step at the 
density functional level (DFT) using the MPW1PW91 functional and 6-31G(d) 
basis set and IEFPCM for simulating the methanol solvent (Gaussian 09 
software package). After the optimization of the geometries at the QM level, a 
visual inspection was performed in order to exclude further possible redundant 
conformers, and then those selected were used for the subsequent computation 
of the 13C and 1H NMR chemical shifts. 
In details, the conformational analysis revealed many degrees of freedom in 
the heptanoid chains connecting the two phenyl moieties, determining different 
geometries to be accounted in the final Boltzmann distribution. Furthermore, 
similar conformers differing for the presence/absence of intramolecular H-
bonds between the hydroxyl groups placed on adjacent carbons on the 
heptanoid chains were energetically weighted in the Boltzmann distribution 
according to the protic solvent (methanol) “continuum model” considered in 
the QM calculations. The diaryl moieties also affected the conformational 
sampling, leading to various conformers specifically differing for the dihedral 
anglesbetween the two aromatic groups and their final arrangements on the 
heptanoid chain (Figure 5.1.1.2). 
 
Figure 5.1.1.2 Two sampled conformations of 68f in both separate and superimposed view 
modes, showing the flexibility of the heptanoid chain. The different relative arrangement of 





Then, the 13C and 1H NMR chemical shifts for each investigated 
diastereoisomer were computed at the density functional level (DFT), using the 
MPW1PW91 functional and 6-31G (d,p) basis set and methanol IEFPCM. The 
specific contribution of each selected conformer was weighted on the final 
Boltzmann distribution according to the related energy. Aromatic 13C and 1H 
were scaled using benzene as reference compound, following the approach 
developed by Pellegrinet et al.,137,138 while the other atoms were scaled taking 
into account tetramethylsilane (TMS). Afterwards, for each atom of the 
investigated molecules, the comparison of the experimental and calculated 13C 
and 1H NMR chemical shifts was performed computing the Δδ parameter:  
Δδ = |δexp - δcalc| 
where, δexp (ppm) and δcalc (ppm) are the 13C/1H experimental and 
calculated chemical shifts, respectively. 
Finally, the relative configuration of each investigated compound was 
determined calculating and comparing the mean absolute errors (MAEs) for all 
the possible diastereoisomers: 
MAE = ∑(Δδ)/n 
specifically defined as the summation through n of the absolute error values 
(difference of the absolute values between corresponding experimental and 
13C-1H chemical shifts), normalized to the number of the chemical shifts 
considered. In this way, the relative configurations of compounds 66-72, shown 
in Table 5.1.1.1, were assigned selecting the related diastereoisomers showing 
the lowest 13C/1H MAE errors. 
Moreover, three known flavonoid derivatives myricetin 3-O-
rhamnpyranoside,1 quercetin 3-O-rhamnopyranoside,1 kaempferol 3-O-
rhamnopyranoside,1 and kaempferol 3-O-(4''-trans-p-coumaroyl)-
rhamnopyranoside, have been also isolated from the leaves of C. avellana. 
On the basis of the ability reported for the well known diarylheptanoid 





inhibit cell growth in malignant cells, the cytotoxic activity of compounds 1-7, 
myricetin 3-O-rhamnpyranoside, quercetin 3-O-rhamnopyranoside, 
kaempferol 3-O-rhamnopyranoside, kaempferol 3-O-(4''-trans-p-coumaroyl)-
rhamnopyranoside and curcumin, used as reference compound, has been 
evaluated in two cancer cell lines, the U2Os and SAOs cells. The two cell lines 
have been selected based on the following criteria: 1) both cell lines have a 
common origin (human osteosarcoma) and they are resistant to apoptotic 
stimuli; 2) they are characterized by a different genetic background relatively 
to p53 gene, being SAOs p53 mutate and U2Os p53 wild-type; 3) both cell 
lines have been largely employed in previous studies to assess the biological 
activity of naturally occurring compounds. The obtained results showed that all 
tested compounds possess EC50 values higher than 150 µM at 24-48 h, 
indicating the absence of cytotoxicity on both cell lines.  
The present results suggest C. avellana leaves as a rich source of phenolic 
compounds, among which highly hydroxylated cyclized diarylheptanoids. 
Since the reported diarylheptanoid derivatives don’t exert cytotoxic activity on 
the selected cancer cell lines, other investigations will be performed to evaluate 
the potential of these compounds as antioxidant agents, and to use the leaves 
of C. avellana as a source of functional ingredients for nutraceutical, herbal, 






Table 5.1.1.113C/1H MAE (ppm)a 
 
# of stereogenic 
centers 











66 2 2 
66a 12S*,14S* 24 1.63 0.22 
  
66b 12R*,14S* 25 1.73 0.28 
67 2 2 
67a 12S*,14S* 19 1.85 0.25 
  
67b 12R*,14S* 18 1.71 0.17 
68 4 8 
68a 8S*,10R*,11R*,12R* 16 4.37 0.36 
 
68b 8S*,10R*,11R*,12S* 17 2.77 0.34 
68c 8S*,10R*,11S*,12R* 15 2.25 0.23 
68d 8S*,10R*,11S*,12S* 17 2.05 0.34 
68e 8S*,10S*,11R*,12R* 18 1.70 0.25 
68f 8S*,10S*,11R*,12S* 15 1.37 0.16 





68h 8S*,10S*,11S*,12S* 18 3.07 0.21 
69 2 2 
69a 8S*,10S* 27 2.62 0.30 
 
69b 8S*,10R* 28 2.08 0.19 
70 2 2 
70a 8S*,10S* 35 2.79 0.16 
  
70b 8S*,10R* 34 2.50  0.14 
71 3 4 
71a 8S*,9R*,12S* 18 3.21 0.31 
 
71b 8S*,9R*,12R* 20 1.50 0.18 
71c 8S*,9S*,12S* 18 2.06 0.23 
71d 8S*,9S*,12R* 20 2.61 0.35 
72 4 8 
72a 8S*,9R*,11R*,12R* 19 3.56 0.34 
  
72b 8S*,9R*,11R*,12S* 22 2.40 0.31 
72c 8S*,9R*,11S*,12R* 21 3.67 0.23 
72d 8S*,9R*,11S*,12S* 22 3.57 0.24 
72e 8S*,9S*,11R*,12R* 20 2.80 0.29 





72g 8S*,9S*,11S*,12R* 19 2.28 0.18 
72h 8S*,9S*,11S*,12S* 21 3.04 0.37 
 
aMAE = Σ[|(δexp – δcalcd)|]/n, summation through n of the absolute error values (difference of the absolute values between corresponding 
experimental and 13C/1H chemical shifts), normalized to the number of the chemical shifts. Values are reported for all the possible relative 












































In order to design and develop new synthetic and natural platforms targeting 
mPGES-1 and acting as anti-inflammatory and anti-cancer agents, we 
employed in silico strategies combined with the evaluation of the biological 
activities by means of in vitro experiments.  
In particular, the computational aspects mainly regard the application and 
elaboration of screening methods, the analysis of structural determinants 
responsible of drug-macromolecule interaction and the design and 
development of new potent bioactive compounds by means of molecular 
docking calculations. For what concerns the biological part, the determination 
of PGE2 synthase activity in microsomes of A549 cells, the determination of 
product formation by 5-LOX in the cell-based and cell-free assay, and the 
determination of eicosanoids production by LC-MS/MS in monocytes and 
polymorphonuclear leucocytes were performed at the Department of 
Pharmaceutical and Medicinal Chemistry of the Friedrich- Schiller University 
in Jena. This approach was successfully applied leading to the identification of 
new potent inhibitors for mPGES-1 enzyme.  
Therefore, our studies were aimed to the discovery of new synthetic 
inhibitors targeting mPGES-1.The attention was focused on this target since it 
is involved in diverse levels and phases of tumor and inflammation process. In 
fact, in some types of cancer, inflammatory conditions are present before a 
malignant change occurs. Conversely, in other types of cancer, an oncogenic 
change induces an inflammatory microenvironment that promotes the 
development of tumors. Regardless of its origin, inflammation in the tumor 
microenvironment has many tumor-promoting effects. It aids in the 
proliferation and survival of malignant cells, promotes angiogenesis and 
metastasis, it subverts adaptive immune responses, and it alters responses to 
hormones and chemotherapeutic agents.  
Thanks to the recently published crystal structures of mPGES-1 enzyme, the 





Molecular docking technique was used for the rational design taking into 
account the analysis of ligand-target interactions and the actual synthetic 
possibilities. The X-ray structures of mPGES-1 in complex with LVJ inhibitor 
and more recently with four different inhibitors, provide us a good starting 
point providing a rationale for understanding the associated structure−activity 
relationships and a structural context for species-associated selectivity.  
After an introduction regarding the derived-NSAIDs side effects 
determining the need of discovering new safe targets (such as mPGES-1), in 
the second chapter we reported the elucidation of new structural features of the 
triazole scaffold through docking calculations on the basis of the data arising 
from structure-based molecular docking experiments. In the course of previous 
studies, we identified a novel class of 1,4-disubstitued 1,2,3-triazoles that 
inhibited mPGES-1 in a cell-free assay with IC50 values in the low µM range. 
Afterwards, we performed a new structure drug design with the aim of 
investigating the influence of the ring-substituent topological position and 
simplifying the mPGES-1 inhibitor structure. The reported results led to the 
identification of compound 24 that showed efficient inhibitory activity and has 
proved the importance of halogen bonding as new key interaction useful for the 
design of this novel triazole derivatives as mPGES-1 inhibitors.  
Moreover, we achieved the identification of different leads from a small 
synthetic library by means of in silico approaches. Docking results determined 
the selection of seven compounds that were able to inhibit mPGES-1. In 
particular, the compounds were tested on mPGES-1 and 5-LOX taking into 
account that dual inhibitors blocking both mPGES-1 and 5-LOX metabolic 
pathways of arachidonic acid are expected to possess clinical advantages over 
the selective inhibitors of enzyme. In particular, a good accordance between 
molecular modeling predictions and biological results was found; four of them 
displayed a considerable inhibition activity, while three of them showed also 





thiazolidine]-2,4'-dione and nitrofuran scaffolds) were further optimized to 
develop new possible mPGES-1 inhibitors. In this way, a series of 
commercially available building blocks were selected in order to decorate the 
selected scaffolds, with the aim of improving the potency and selectivity of the 
optimized ligands . Two compounds from spiro[indoline-3,2'-thiazolidine]-
2,4'-dione series were identified displaying an increase of the inhibitory activity 
(mPGES-1 inhibition of 30% and 50% respectively) with respect to the lead 
compound, and further one compound from nitrofuran derivates showing 
highest inhibitory activities with an IC50 of 1.37 ± 0.7 µM. The determination 
of the production of 5-LOX metabolites is ongoing. 
At the end of the second chapter, we reported the identification of biphenilic 
scaffold as new synthetic platform targeting mPGES-1, which was carried out 
by virtual screening on the basis of a drug-receptor analysis, taking into account 
the more recent crystal structure of the enzyme74 and using Autodock-Vina and 
Glide molecular modeling software. The rational design of this potential 
scaffold has guided the identification of 5 potent inhibitors of the enzyme, 
validated with biological assays. In particular, compounds 44 and 47 showed 
the strongest inhibitory activity with IC50 = 0.26 ± 0.05 and 0.18 ± = 0.03 µM, 
respectively. Due to the fact that the nitro groups can influence the cytotoxicity 
and the pharmacokinetic, two of them were further optimized to replace the 
nitro groups by more suitable residues, but causing the lack of inhibitory 
activity in enzymatic assay.  
On the basis of the encouraging results regarding the identification of new 
synthetic platforms targeting mPGES-1, in the third chapter we reported the 
evaluation of the inhibitory activity of natural molecular platforms already 
recognized as mPGES-1 blocking agents. Accordingly, molecular docking was 
used to rationalize the binding modes of several compounds with known 
biological activities. As first point we reported the theoretical evaluation of a 





to the identification of 12-O-methylsalvipalestinoic acid as bioactive 
compounds. These compounds were then tested for inhibition of 5-LOX 
activity in a cell-based assay using PMNL and they did not affect the 
production of 5-LOX metabolites.  
Another line of this project has regarded in vivo and in vitro biological 
evaluation of anti-inflammatory response of carnosol and carnosic acid and in 
silico analysis of their mechanism of action. The compounds were analyzed 
and a full rationalization of their binding mode was reported. The effects of 
these two compounds were mainly due to the inhibitory activity on arachidonic 
related metabolites production, and they might contribute to the anti-
nociceptive, anti-inflammatory and antitumoral property of others Salvia spp. 
containing these diterpenoids. In conclusion, molecular docking and biological 
studies have allowed the rationalization of the molecular mechanism of 
carnosol and carnosic acid, which are related to the biological activity on some 
key enzymes involved in the arachidonic acid cascade such as mPGES-1, 5-
LOX and COXs. In fact, the multiple suppression might be superior over single 
inhibition in terms of efficacy as well as in terms of side effects. 
Another study has concerned the molecular mechanism of tanshinone IIA 
and cryptotanshinone in platelet anti-aggregating effects performing an 
integrated study of pharmacology and computational analysis in order to 
determinate the target responsible of their observed activity. Cryptotanshinone 
is able to inhibit the rat platelet aggregation in a concentration dependent 
manner and it also showed a G-coupled P2Y12R receptor antagonistic activity 
as demonstrated by docking studies. This computational method was also 
employed for tanshinone IIA demonstrating also for this diterpenoid an 
interaction with the same receptor. Pharmacological and structure-activity 
relationship analysis have demonstrated that these natural diterpenoids are 





Finally, the combination of NMR spectroscopy163b,139 and quantum 
mechanical calculation140 (coupling constant, chemical shift) was successfully 
used in order to assign the relative configuration patterns of seven natural 
products giffonins J-P. These deterpenoids were isolated and extracted from 
the leaves of Coryllus avellana. Hence the relative configurations of the 
giffonins J-P were assigned by a combined QM/NMR approach, comparing the 
experimental 13C/1H-NMR chemical shift data and the related predicted values.  
Technical details about the employed computational techniques and 


































































































A.1 Molecular docking 
Computational methodologies have become a crucial component in drug 
discovery, from virtual screening for hit identification to lead compound 
optimization. One key methodology is the molecular docking that consists in 
the prediction of ligand conformation and orientation within a targeted binding 
site. The molecular docking is based on the requirement that the 3D structure 
of the macromolecule is known. Many different programs have been 
developed, of which DOCK,141 FlexX,142 GOLD,143120 Autodock,144,145,146 
Autodock Vina,147 and Glide122148 are among the most popular. The 
mentioned tools are based on a range of different concepts, and each comes 
with its own set of strengths and weaknesses. One feature most docking 
programs share, however, is that they position a flexible ligand into a rigid 
binding site. Computational feasibility is the main reason for utilizing a rigid 
macromolecule in the docking calculations, as the number of freedom degrees 
that have to be considered grows exponentially with the number of accessible 
receptor conformations. Most molecular docking software have two key parts: 
(1) a search algorithm and (2) a scoring function.149 For molecular docking to 
be useful in drug discovery, these key parts should be both fast and accurate. 
These two requirements are often in opposition to each other, requiring 
necessary compromises that commonly end in ambiguous results or failure.150 
The search algorithm samples different ligand orientations and 
conformations fitting the macromolecular binding site. This step is complicated 
by the number of freedom degrees contained in the small molecule, increasing 
the conformational space to sample. The search methods can be grouped in 
three categories: systematic methods, random or stochastic methods, and 
simulation methods. The systematic search algorithms try to explore all the 
degrees of freedom in a molecule, but they face the problem of huge number 
of generated conformations.151 The random methods (often called stochastic 





population of ligands. A newly obtained ligand is evaluated on the basis of a 
pre-defined probability function. Two popular random approaches are Monte 
Carlo and genetic algorithms. About simulations search methods, molecular 
dynamics is currently the most popular approach. However, molecular 
dynamics simulations are often unable to cross high-energy barriers within 
feasible simulation time periods, and therefore might only accommodate 
ligands in local minima of the energy surface.152 Therefore, an attempt is often 
made to simulate different parts of a protein–ligand system at different 
temperatures.153 Another strategy for addressing the local minima problem is 
starting molecular dynamics calculations from different ligand positions. In 
contrast to molecular dynamics, energy minimization methods are rarely used 
as stand-alone search techniques, as only local energy minima can be reached, 
but often complement other search methods. The scoring function aims to 
evaluate the results of the search algorithm predicting the affinity for the 
biological target. This evaluation is very difficult because the binding process 
is governed by enthalpic and entropic factors and one or of them can 
predominate. Other elements can affect the scoring method, such as limited 
resolution of crystallographic targets, inherent flexibility, induced fit or other 
conformational changes that occur on binding and the participation of water 
molecules in macromolecule–ligand interactions. Three classes of scoring 
functions are currently applied: force field-based, empirical and knowledge-
based scoring functions.  
Molecular mechanics force fields usually quantify the sum of two energies, 
the macromolecule–ligand interaction energy and internal ligand energy (such 
as steric strain induced by binding). Most force field scoring functions only 
consider a single protein conformation, which makes it possible to omit the 
calculation of internal protein energy, which greatly simplifies scoring. The 





Waals terms, and is some software (AutoDock, Gold) take into account the 
hydrogen bond formation between drug and biological target. 
The van der Waals potential energy for the general treatment of non-bonded 
interactions is often modeled by a Lennard–Jones 12–6 function (Equation 
1.1): 
 
















Equation 1. 1 
 
where ε is the well depth of the potential and σ is the collision diameter of 
the respective atoms i and j. The exp(12) term of the equation is responsible for 
small-distance repulsion, whereas the exp(6) provides an attractive term which 
approaches zero as the distance between the two atoms increases. 
The Lennard–Jones 12–6 function is also used to describe the hydrogen 
bond in macromolecule-ligand complex, but compared to the Van der Waals 
function, is less smooth and angle dependent. 
 
Figure 1. 5Schematic representation of functions used to model pair-wise interactions that 
contribute to binding. Interactions are calculated as a function of the distance (rij) between two 
atoms i and j. a) van der Waals interaction given by a 12–6 Lennard–Jones potential (note the 
smoother attractive part of the potential compared to hydrogen bond term). B) hydrogen bond 





like (blue) or opposite (black) charges of same magnitude calculated using a distance 
dependent dielectric constant. 
 
The electrostatic potential energy is represented as a summation of 
Coulombic interactions, as described in equation 1.2: 
 











Equation 1. 2 
 
where N is the number of atoms in molecules A and B, respectively, and q 
the charge on each atom. The functional form of the internal ligand energy is 
typically very similar to the protein–ligand interaction energy, and also 
includes van der Waals contributions and/or electrostatic terms. 
Empirical scoring functions work on the sum of several parameterized 
functions to reproduce experimental data. The design of empirical scoring 
functions is based on the idea that binding energies can be approximated by a 
sum of individual uncorrelated terms. The coefficients of the various terms are 
obtained from regression analysis using experimentally determined binding 
energies and X-ray structural information. 
By using the knowledge-based scoring functions protein–ligand complexes 
are modeled using relatively simple atomic interaction-pair potentials. A 
number of atom-type interactions are defined depending on their molecular 
environment. 
 
A.1.1. Autodock Vina: an Overview 
There are numerous molecular docking software applications that utilize 
different searching and scoring algorithms and AutoDock Vina is currently one 





compound libraries.155 For the purposes of this project the software 
AutodockVina147 and Glide have been used, where the differences between 
them are related to the speed, macromolecule sidechains flexibility, 
optimization of the free-energy scoring function based on a linear regression 
analysis, AMBER force field, larger set of diverse protein-ligand complexes 
with known inhibition constants; moreover the Lamarckian Genetic Algorithm 
(LGA) is a big improvement on the Genetic Algorithm, and both genetic 
methods are much more efficient and robust than SA in the new version of the 
software. 
AutoDock Vina,147 is a new open-source program for drug discovery, 
molecular dockingand virtual screening, offering multi-core capability, high 
performance and enhanced accuracy and ease of use. Vina uses a sophisticated 
gradient optimization method in its local optimization procedure. The 
calculation of the gradient effectively gives the optimization algorithm a “sense 
of direction” from a single evaluation. In the spectrum of computational 
approaches to modeling receptor ligand binding molecular dynamics with 
explicit solvent, molecular dynamics and molecular mechanics with implicit 
solvent, molecular docking can be seen as making an increasing trade-off of 
the representational detail for computational speed.156 Among the assumptions 
made by these approaches is the commitment to a particular protonation state 
of and charge distribution in the molecules that do not change between, for 
example, their bound and unbound states. Additionally, docking generally 
assumes much or all of the receptor rigid, the covalent lengths, and angles 
constant, while considering a chosen set of covalent bonds freely rotatable 
(referred to as active rotatable bonds here). Importantly, although molecular 
dynamics directly deals with energies (referred to as force fields in chemistry), 
docking is ultimately interested in reproducing chemical potentials, which 
determine the bound conformation preference and the free energy of binding. 





energy profile but also by the shape of the profile and the temperature.157 
Docking programs generally use a scoring function, which can be seen as an 
attempt to approximate the standard chemical potentials of the system. When 
the superficially physics-based terms like the 6–12 van der Waals interactions 
and Coulomb energies are used in the scoring function, they need to be 
significantly empirically weighted, in part, to account for this difference 
between energies and free energies.157 
The afore mentioned considerations should make it rather unsurprising 
when such superficially physics-based scoring functions do not necessarily 
perform better than the alternatives. This approach was seen to the scoring 
function as more of “machine learning” than directly physics-based in its 
nature. It is ultimately justified by its performance on test problems rather than 
by theoretical considerations following some, possibly too strong, 
approximating assumptions 
The general functional form of the conformation-dependent part of the 
scoring function AutoDock Vina is designed to work with is: 
𝑐 = ∑ 𝑓𝑡𝑖𝑡𝑗
𝑖<𝑗
(𝑟𝑖𝑗) 
Equation 1. 3 
 
where the summation is over all of the pairs of atoms that can move relative 
to each other, normally excluding 1–4 interactions, i.e., atoms separated by 
three consecutive covalent bonds. Here, each atom i is assigned a type ti, and a 
symmetric set of interaction functions fti-tj of the interatomic distance rij should 
be defined. 
This value can be seen as a sum of intermolecular and intramolecular 
contributions: 
 





Equation 1. 4 
 
The optimization algorithm attempts to find the global minimum of c and 
other low-scoring conformations, which it then ranks. 
The predicted free energy of binding is calculated from the intermolecular 
part of the lowest-scoring conformation, designated as 1: 
 
𝑠1 =  𝑔 (𝑐1  −  𝑐𝑖𝑛𝑡𝑟𝑎1) =  𝑔(𝑐𝑖𝑛𝑡𝑒𝑟1) 
Equation 1. 5 
 
where the function g can be an arbitrary strictly increasing smooth possibly 
nonlinear function. 
In the output, other low-scoring conformations are also formally given s 
values, but, to preserve the ranking, using cintra of the best binding mode: 
 
𝑠𝑖 =  𝑔(𝑐𝑖  −  𝑐𝑖𝑛𝑡𝑟𝑎1) 
Equation 1. 6 
 
For modularity reasons, much of the program does not rely on any particular 
functional form of fti-tj interactions or g. Essentially, these functions are passed 
as a parameter for the rest of the code. 
In summary the evaluation of the speed and accuracy of Vina during flexible 
redocking of the 190 receptor-ligand complexes making up the AutoDock 4 
training set showed approximately two orders of magnitude improvement in 
speed and a simultaneous significantly better accuracy of the binding mode 
prediction. In addition, Vina can achieve near-ideal speed-up by utilizing 
multiple CPU cores. However, AutodockVina does not provide very good 
weight of the energetic contribution derived from the hydrogen bond and 





A.1.2. Glide: an Overview 
Glide uses a hierarchical series of filters to search for possible locations of 
the ligand in the active-site region of the receptor. The shape and properties of 
the receptor are represented on a grid by several different sets of fields that 
provide progressively more accurate scoring of the ligand poses. 
Conformational flexibility is handled in Glide by an extensive conformational 
search, augmented by a heuristic screen that rapidly eliminates unsuitable 
conformations, such as conformations that have long-range internal hydrogen 
bonds. The second stage of the hierarchy begins by examining the placement 
of atoms that lie within a specified distance of the line drawn between the most 
widely separated atoms (the ligand diameter). This is done for a pre-specified 
selection of possible orientations of the ligand diameter. If there are too many 
steric clashes with the receptor, the orientation is skipped.Next, rotation about 
the ligand diameter is considered, and the interactions of a subset consisting of 
all atoms capable of making hydrogen bonds or ligand-metal interactions with 
the receptor are scored (subset test). If this score is good enough, all 
interactions with the receptor are scored.The scoring in these three tests is 
carried out using Schrödinger’s discretized version of the ChemScore empirical 
scoring function.Only a small number of the best refined poses (typically 100-
400) is passed on to the third stage in the hierarchy-energy minimization on the 
pre-computed OPLS-AA van der Waals and electrostatic grids for the receptor. 
Finally, the minimized poses are re-scored using Schrödinger’s proprietary 
GlideScore scoring function. GlideScore is based on ChemScore, but includes 
a steric-clash term, adds buried polar terms devised by Schrödinger to penalize 
electrostatic mismatches, and has modifications to other terms:  
GScore = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + 
RotB + Site 
The choice of best-docked structure for each ligand is made using a model 





predicted by GlideScore, and (for flexible docking) the internal strain energy 
for the model potential used to direct the conformational-search algorithm.  
It is important to underline in this phase of the studies description that the 
molecular docking methodology was used for the design and development of 
new molecular platforms with potential anticancer and anti-inflammatory 
activities as mPGES-1 (see chapter 3) inhibitors. In particular,for the 
elucidation of new structural features of the triazole scaffold we used the crystal 
structure PDBcode: 4AL1(paragraph 3.1) and Glide software,for the 
rationalization of the binding mode of a small synthetic library (paragraph 3.2) 
and for the development of new librariesby a series of 71- 244 derivates 
(paragraph 3.3) we used the crystal structure PDB code: 4AL1 and Autodock 
Vina software. In the structure-based rational drug design for the development 
of new potent mPGES-1 inhibitors we used the crystal structure PDBcode: 
4YK5 (paragraph 3.4) and Autodock Vina software.Alongside this application, 
in this results description, the molecular docking was also used to rationalize 
the binding modes and the mechanism of action of a small pool of natural 
compounds as mPGES-1 (PDBcode: 4AL1, Autodock Vina) (paragraph 4.1), 
of carnosol and carnosic acidas mPGES-1, COXs, 5-LOX (PDB code: 4AL1, 
3N8X, 1CX2, 3O8Y respectively, Glide software) inhibitor(paragraph 4.2), of 
cryptotanshinone and tanshinone IIA inhibitors of P2Y12R 1 (PDB code: 4NTJ, 
Glide software) (paragraph 4.3)(Chapter 4). 
 
A.2 Biological evaluation and assay systems 
In order to study the ability of the compounds to directly inhibit 5-LOX, a 
cell-free assay using purified human recombinant 5- LOX enzyme and 
arachidonic acid (20 mM) as the substrate was applied. To study the inhibitory 
potency on 5-LOX product formation in intact cells, human neutrophils 
stimulated with the Ca2+- ionophore A23187 together with exogenous AA (20 





used microsomes of A549 cells stimulated with PGH2 (final concentration, 20 
μM). To determinate the eicosanoids production in intact cells, the analysis 
were assessed in PMNL stimulated with the Ca2+- ionophore A23187 20 mM 
and in monocytes stimulated by LPS in medium 5% FCS. 
 
A.2.1. Induction of mPGES-1 and determination of PGE2 synthase 
activity in microsomes of A549 cells 
Preparation of A549 cells and determination of the activity of mPGES-1 was 
performed as described previously.106 In brief, IL-1β-treated A549 cells 
overexpressing mPGES-1 were sonicated and the microsomal fraction was 
prepared by differential centrifugation at 10,000g for 10 min and at 174,000g. 
The resuspended microsomal membranes were preincubated with the test 
compounds or vehicle (DMSO). After 15 min, PGE2 formation was initiated 
by addition of PGH2 (final concentration, 20 μM). After 1 min at 4 ˚C, the 
reaction was terminated, and PGE2 was separated by solid-phase extraction 
(RP-18 material) and analyzed by RP-HPLC as described. The solid phase 
extraction was performed with RP18-columns containing a polymeric 
reversed- phase. The sample was added after conditioning the column with 1 
ml 100% Methanol and 1 ml H2O. After washing the columns two times with 
0,5 ml H2O, eicosanoids were eluted with 300 µl 100% Methanol. The 
supernatant obtained after two centrifugation steps (15000 x g, 5 min, 4°C) was 
used for the RP-HPLC run. 
 
A.2.2. Isolation of polymorphonuclear leukocytes and peripheral 
blood mononuclear cells from buffy coats 
Human polymorphonuclear leukocytes (PMNL) and peripheral blood 
mononuclear cells (PBMC) were freshly isolated from whole warm venous 
blood, collected from adult female healthy volunteers at Universitatkilikum 





diluted with 10 ml of PBS-dextran solution (5%, w/m), and stored at RT for 40 
min to allow the erythrocytes precipitation. Then, 10 ml of lymphocyte 
separation medium were overlaid with 40 ml of the supernatant and centrifuged 
(2000 rpm, 20 min, RT and w/o brake) to separate the different cell types. 
 
 
Figure A.3.1 Density Centrifugation (left to right) 
 
The polymorphonuclear leukocytes are localized in the pellet fraction that 
was then washed with PBS and centrifuged (1200 rpm, 10 min, 4°C). The 
erythrocytes remaining in the pellet were lysed using ice-cold water, vortexing 
the suspension for 45 sec. This process was stopped by adding the fourfold 
amount of PBS to prevent the lysis of the leukocytes. The PMNL were washed 
again as described previously, diluted with PBS containing glucose (0.1%, 
w/v). The isolation procedure was strictly performed at 4°C. 
PBMC are localized in the ring fraction that after collection, were washed 3 
times with cold PBS; then monocytes were separated by adherence for 1 h at 
37°C to culture flasks (2×107 cells/ml RPMI 1640 medium containing 2 mM l-
glutamine and 50 µg/ml penicillin/streptomycin), which gave a purity of>85%, 
defined by properties of forward and side scatter of light and detection of the 





resuspended in ice-cold PBS plus 1 mg/ml glucose (PG buffer) or in PG buffer 
containing 1 mM CaCl2 (PGC buffer). 
 
A.2.3. Determination of product formation by 5-LOX in the cell-
based assay by HPLC 
For assays of intact cells stimulated with Ca2+ -ionophore A23187, 5 × 106 
freshly isolated neutrophils were resuspended in 1 mL PGC buffer. After pre-
incubation with the compounds (15 min, 37°C), 5-LOX product formation was 
started by addition of 1 mM CaCl2 and 2.5 μM A23187 plus AA at the indicated 
concentrations respectively. After 10 min at 37°C, the reaction was stopped by 
addition of 1 mL of methanol. The 5-LOX metabolites formed were extracted 
and analysed by HPLC as described previously. 5-LOX product formation is 
expressed as ng of 5-LOX products per 106 cells, which includes LTB4 and all 
of its trans isomers, 5(S),12(S)-di-hydroxy-6,10-trans-8,14-cis-
eicosatetraenoic acid (5(S),12(S)-DiHETE), and 5(S)-hydro(pero)xy-6-trans- 
8,11,14-cis-eicosatetraenoic acid (5-H(p)ETE). Cysteinyl LTs C4, D4 and E4 
were not detected, and oxidation products of LTB4 were not determined. 
 
A.2.4. Determination of product formation by 5-LOX in the cell-
free assay by HPLC 
Expression of 5-LOX was performed in E. coli JM 109 cells, transfected 
with pT3-5LO, and purification of 5-LOX was performed as described 
previously. In brief, cells were lysed by incubation in 50mM triethanolamine/ 
HCl pH 8.0, 5 mM EDTA, soybean trypsin inhibitor (60 mg/ml), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and lysozyme (500 mg/ml), 
homogenized by sonication (3 15 s) and centrifuged at 19,000 g for 15 min. 
Proteins including 5-LOX were precipitated with 50% saturated ammonium 
sulfate during stirring on ice for 60min. The precipitate was collected by 





PBS containing 1 mM EDTA. After centrifugation at 100,000 g for 70min at 
4˚C, the 100,000 g supernatant was applied to an ATP-agarose column (Sigma 
A2767), and the column was eluted as described previously. Partially purified 
5-LOX was immediately used for in vitro activity assays. Samples were 
preincubated with the test compounds or vehicle (0.1% DMSO) as indicated. 
After 10 min at 4 ˚C, samples were pre-warmed for 30 s at 37 ˚C, and 2 mM 
CaCl2 plus 20 mM AA was added to start 5-LOX product formation. The 
reaction was stopped after 10 min at 37 ˚C by addition of 1 ml ice-cold 
methanol, and the formed metabolites were analyzed by HPLC as described. 5-
LOX products include the all-trans isomers of LTB4 as well as 5-HPETE and 
its corresponding alcohol 5-HETE. 
 
A.2.5. Determination of eicosanoids production in PMNL and 
monocytes by UPLC-MS/MS 
To determinate the eicosanoids production in PMNL and monocytes, the 
analysis were assessed in PMNL stimulated with the Ca2+- ionophore A23187 
and in monocytes stimulated by LPS. Freshly isolated neutrophils158 (5 × 
106/mL) were preincubated with the test compounds (dissolved in DMSO) for 
10 min at 37 °C, then were stimulated with 2.5 μM Ca2+-ionophore A23187 for 
15 min at 37 °C, we stopped the reaction through the addition of 1 mL of 
methanol and the extraction of the eicosanoids were performed by SPE after 
the addition of 530 µM PBS/HCl and PGB1 100 ng/ml.. PBMC frEshly isolated 
from buffy coats of human blood were plated in 170 cm2 culture flask in RPMI 
culture medium (RPMI 1640 containing 100 U/mL penicillin, 100 mg/mL 
streptomycin, 2 mM L-glutamine and 2% (v/v) human serum) to let them 
adhere. After 1.5 h at 37 ̊ C and 5% CO2, monocytes were collected by scraping 
of the flask and 1.5×106 /mL of monocytes were stimulated with LPS 10 ng/mL 
for 24 h in order to measure the production of mPGES-1 and COXs 





stimulus, For measurement of eicosanoids levels supernatants were collected 
after centrifugation (2000 g, 4 8C, 10 min). Then extracted by SPE and 
analysed by UPLC-MS/MS.  
Ultra-performance liquid chromatography tandem mass spectrometry 
(UPLC-MS/MS) analyses were carried out on an Acquity UPLC BEH C18 
column (1.7 µm, 2.1×50 mm, Waters, Milford, MA, USA) using an 
AcquityTM UPLC system (Waters) and a QTRAP 5500 Mass Spectrometer 
(AB Sciex, Darmstadt, Germany) equipped with a Turbo V™ Source and 
electrospray ionization (ESI) probe. 
Cell products (4 µl injection) were separated at a flow rate of 0.8 ml/min 
and a column temperature of 45 °C. The solvents for the mobile phase were 
water/acetonitrile (90/10; solvent A) and acetonitrile (solvent B) both acidified 
with 0.07% (v/v) formic acid. Isocratic elution at A/B=30% was performed for 
2 min, and followed by a linear gradient to 70% B within 5 min. HPLC solvents 
were from VWR (Darmstadt, Germany). 
Lipid mediators were detected by multiple reaction monitoring in the 
negative ion mode using a dwell time of 10 ms. The ion spray voltage was set 
to 4500 V, the heater temperature to 500 °C, the declustering potential to 50–
120  eV, the  entrance potential to 10  eV and the collision cell exit potential to 
11–22 eV, the spray gas pressure to 50 psi, the Turbo V gas pressure to 80 psi 
and the curtain gas pressure to 20 psi. 
Automatic peak integration was performed with Analyst 1.6 software (AB 
Sciex, Darmstadt, Germany) using IntelliQuan default settings. Data were 
normalized on the internal standard PGB1 and are given as percentage of 
positive control. 
The reported method was optimized not for absolute quantification of 
eicosanoids, but for the analysis of mediator lipids production in PMNL and in 






A.2.6. Induction and assessment of carrageenan-induced 
hyperalgesia 
Acute inflammation was induced in the right hind paw by injecting 
subcutaneously (s.c.) 50μl of freshly prepared solution of 1% carrageenan. The 
left paw received 50μl of saline, which served as control. The response to 
inflammatory pain was determined by measuring the mechanical nociceptive 
pressure by the paw pressure test via a commercially available analgesiometer 
(Ugo Basile, Italy). The apparatus was set up to apply a force of 0-250 g, 
increasing from zero. The nociceptive threshold was taken as the end point at 
which mice vocalized or struggled vigorously. Carnosol and carnosic acid were 
administrated subcutaneously (s.c.) in a dose dependent manner (1-100 
μg/20μl) 30 min before1% carrageenan (50μl; s.c.) into the dorsal hind paw of 
the mice and the pressure threshold was observed at 0.5, 1, 3 and 4h. The time 
selection was made based on the preliminary studies. A change in the 
hyperalgesic state was calculated as a percentage of the maximum possible 
effect (% MPE) from the formula: [(P2-P1)/(P0-P1) × 100], where P1 and 
P2 - and post-drug paw withdrawal thresholds respectively, and 
P0 was the cut-off (250 g). 
 
A.2.7. Formalin test 
The procedure used has been previously described. Subcutaneous injection 
of a dilute solution of formalin (1%, 20 μl/paw) into the mice hind paw evokes 
nociceptive behavioral responses, such as licking, biting the injected paw or 
both, which are considered indices of pain. The nociceptive response shows a 
biphasic trend, consisting of an early phase occurring from 0 to 10 min after 
the formalin injection, due to the direct stimulation of peripheral nociceptors, 
followed by a late prolonged phase occurring from 20 to 40 min, which reflects 
the response to inflammatory pain. During the test, the mouse was placed in a 





administration to allow it to acclimatize to its surroundings. The total time (s) 
that the animal spent licking or biting its paw during the formalin-induced early 
and late phase of nociception was recorded. Carnosol and carnosic acid were 
administrated subcutaneously (s.c.) (100 μg/20μl) 30 min before formalin 
injection (20μl; s.c.). 
 
A.2.8. In vitro platelet aggregation assay 
In vitroplatelet aggregation was measured according to the turbidimetric 
method, using two-channel aggregometer (Chrono-Log, Corporation, Mod. 
490, USA). Blood anticoagulated with 3.2% sodium citrate (1:9 citrate/blood, 
v/v) was withdrawn from male Wistar rats (anesthetized by enflurane) by 
cardiac puncture. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) 
were prepared as previously described (Maione et al., 2013, 2014). Briefly, 
PRP was obtained by centrifugation at 800 rpm for 15 min at 25 °C. PPP was 
prepared from the precipitated fraction of PRP by centrifugation at 2000 rpm 
for 20 min at 25 °C. PRP was adjusted to 3×108 platelets/ml. Next, 250 μl of 
PRP were incubated at 37 °C for 1 min in the cuvette with 20 μl of CRY 
solution at final concentration of 0.5, 5 and 50 μM. CRY-vehicle (0.3% DMSO 
in distilled water) was used as control. After incubation, platelet aggregation 
was induced by the addition of 20 μL ADP (3 μM). The maximum platelet 
aggregation rate was recorded within 10 min with continuous stirring at 37 °C. 
The light transmittance was calibrated with PPP. The percentage (%) of 
inhibition of platelet aggregation was calculated by the following formula: 
[(X−Y)/X] ×100%. X was the maximum aggregation rate of vehicle-treated 
PRP; Y was the maximum aggregation rate of sample-treated PRP and was 
expressed in terms of AUC (% of total response duration from reagent 
addition).Statistical analysis: all assays were repeated at least in triplicate and 
the results were expressed as mean± standard error of mean (SEM). Results 





Bonferroni׳s test for multiple comparisons. In some cases, One Sample t-test 
was used to evaluate significance against the hypothetical zero value. The 
analysis was performed using GraphPad Prism Software version 4.0. P values 
less than 0.05 were considered significant. 
A.2.9. Cell culture and viability assay 
The U2Os and SAOs cell lines, derived from human osteosarcomas22,23 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS; Life Technologies, Monza, 
Italy), 1% L-glutamine, 1% penicillin, 1% streptomycin (Life Technologies) at 
37°C, in a 5% CO2 humidified atmosphere and harvested at approximately 
90% confluence. 
 
A.3 Quantum Mechanical Calculation of NMR Parameters in 
the Stereostructural Determination of Natural Products 
Many molecular properties of organic compounds, such as chemical 
reactivity and catalytic, biological, and pharmacological activities, are 
critically affected not only by their functional groups but also by their spatial 
position. Thus, the disclosure of the relative configuration has a great impact 
in the full understanding of their chemical behaviours. Different approaches to 
determine the exact structure and/or configuration of organic products have 
been devised.159,160,161The total synthesis has played a primary role in the 
structural assignment and revision but its drawback is represented by the 
additional costs in terms of time and money. For these reasons, a series of new 
and more rapid methods that take advantage of the information deriving from 
nuclear magnetic resonance (NMR), circular dichroism (CD), X-ray 
crystallography, and mass spectrometry (MS), have shown to be a valid 
alternative to the classical chemical approach. 
In this field, NMR spectroscopy is one of the most employed tool, since 





fundamental information on the configurational and conformational 
arrangement of organic molecules. For example, the 3JH-H coupling constants 
between protons separated by three bonds depend on the dihedral angles, 
following the well-known Karplus equation.162 Moreover, the Nuclear 
Overhauser Effect (NOE)163 provides information of the 3D spatial 
arrangement of the nuclei, clarifying the geometrical information on the 
relative positions of the atoms in the analysed molecule. Thus, the evaluation 
of simple NMR parameters, such as proton-proton J-coupling values, chemical 
shifts, and/or nuclear Overhauser effect intensities allows to determine the 
configuration of cyclic compounds with three- to six-membered rings 
presenting a predictable conformational behaviour. Polysubstitued opened 
chains and macrocycles, constitute a more difficult cases of relative 
configurational assignment, because the stereochemical analysis is 
complicated by the geometrical uncertainty of such types of flexible systems.  
For the above situations, different NMR-based methods, such as the 
quantum mechanical calculation of NMR parameters,161,164,165 has been 
proposed for the relative (and/or absolute) configurational assignment of 
organic molecules. In the last years, great advances have been made in 
developing QM methods of chemical interest able to predict molecular 
properties. In particular, the quantum mechanical calculations of NMR 
parameters have been used as an emerging strategy for the assignment of 
relative configuration of organic molecules, based on the high accuracy in the 
reproduction of experimental NMR properties achieved also at a low 
demanding level of theory.166,167 It is noteworthy that, besides the development 
and application of QM approach for structural studies, fast empirical methods 
have been devised to predict NMR chemical shifts.168 These empirical methods 
are based on fast calculation algorithms169 that can generate a set of possible 
structural hypotheses with the average deviation between calculated and 





empirical NMR chemical shift predictions could be useful with large-sized 
molecules or in presence of very flexible compounds for which different 
conformers have to be considered in the more time consuming QM 
calculations. Moreover, these empirical methods can be applied as filter to 
narrow the number of stereoisomers to be accurately verified by other methods 
such as X-ray, total synthesis, QM approaches. 
The 13C-based protocol (Figure A.3.1), used in this project, consists of four 
fundamental steps: (a) conformational search and a preliminary geometry 
optimization of all the significantly populated conformers of each 
stereoisomer; (b) final geometry optimization of all the species at QM level; 
(c) GIAO (gauge including atomic orbital)170 13C NMR calculations of all the 
so-obtained structures at QM level; (d) comparison of the Boltzmann averaged 
NMR parameter calculated for each stereoisomer with those experimentally 
measured for the compound under examination. This protocol could be used 
also for the prediction and comparison of 1H NMR chemical shift data, and it 
has been devised for flexible systems considering the importance of the 
contribution of all significant conformers to predict a chemical-physical 
property and the theory level used to calculate the energy of the single 
geometrical isomers.164,165 Considering the simple case of a molecule with a 
couple of two adjacent stereocenters, the first step is to build two 







Figure A.3.1 Schematization of protocol used for the determination of relative 
configuration in organic compounds, based on 13C calculation at QM level of theory. 
 
The conformational sampling is performed at empirical theory level,171 
generally through molecular dynamics (MD) or by Monte Carlo Multiple 
Minimum methods (MCMM).172 
A preliminary geometry optimization is run at empirical level (molecular 
mechanics, MM) or semi-empirical level (AM1,173 PM3174 or other) on all 
found conformers for each diastereoisomer, followed by a QM optimization 
step. On the so obtained geometries the 13C/1H NMR chemical shift for each 
stereoisomer is calculated and the theoretical data are extrapolated taking into 
account the Boltzmann-weighted average derived from the energies of the 
single conformers. The calculated values are compared with the experimental 
NMR data and the relative (or absolute) configuration is determined based on 
the best fit between theoretical and experimental data set given by one of the 
two structural hypothesis. 
Following the same key steps described for 13C/1H-based protocol, the 
calculation of homo- and heteronuclear coupling constants can be carried out 





details, each global minimum conformer undergoes a full geometry 
optimization using the DFT theoretical level175 and then, on the obtained 
geometries, the calculation of the J couplings is performed taking into account 
the contributions of the following interactions: Fermi contact (FC), 
paramagnetic spin-orbit (PSO), diamagnetic spin-orbit (DSO), and spin-dipole 
(SD). Based on the Boltzmann distribution of the conformers, the calculated J-
coupling values are extrapolated and then compared to the experimental data 
set, suggesting the relative configuration of the examined compound. For large 
molecular systems, presenting many stereocenters, it is suggested that, given 
the prohibitive computational requirement for a simultaneous consideration of 
all combinations of the possible conformations and configurations, the 
molecule can be dissected into appropriately 2-C fragments prior to the J-
coupling calculations,176 as for the Murata’s method. Each reduced subsystem 
is treated like an entire molecule: a geometry optimization step, followed by 
3JH-H and 
2,3JC-H calculations, is performed for each staggered rotamer. It is only 
one of the six calculated data sets that should display a satisfactory agreement 
with the experimental values. Differently from the original J-based approach 
proposed by Murata, for which it is impossible to distinguish the antierythro 
from the antithreo arrangement on the basis of the sole evaluation of the J 
coupling values, the quantitative analysis of the calculated vs the experimental 
data allows the relative configurational assignment for the right anti rotamer.  
 
A.3.1. Computational details in determination of relative 
configuration of giffonins J-P 
Maestro 9.6177 was used to build the chemical structures of all possible 
relative diastereoisomers of compounds 66-72. Optimization of the 3D 
structures was performed with MacroModel 10.2177 using the OPLS force 
field178 and the Polak-Ribier conjugate gradient algorithm (PRCG, maximum 





In particular, for compounds 66, 67, 69 and 70, which have two stereo-
chemical centers, two possible diasteroisomers were considered:  
- 66a (12S*,14S*), 66b (12R*,14S*); 
- 67a (12S*,14S*), 67b (12R*,14S*); 
- 69a (8S*,10S*), 69b (8S*,10R*); 
- 70a (8S*,10S*), 70b (8S*,10R*). 
For compound 71, possessing three stereo-chemical centers, four possible 
diasteroisomers were considered:  
- 71a (8S*,9R*,12R*), 71b (8S*,9R*,12S*), 71c (8S*,9S*,12R*) and 
71d (8S*,9S*,12S*). 
Moreover, for compounds 68, possessing four stereo-chemical centers, eight 
diastereoisomers were accounted:  
- 68a (8S*,10R*,11R*,12R*), 68b (8S*,10R*,11R*,12S*), 68c 
(8S*,10R*,11S*,12R*), 68d (8S*,10R*,11S*,12S*), 68e 
(8S*,10S*,11R*,12R*), 68f (8S*,10S*,11R*,12S*), 68g 
(8S*,10S*,11S*,12R*), 68h (8S*,10S*,11S*,12S*); 
For compound 72, which has five stereo-chemical centers with one plane of 
simmetry, eight possible diasteroisomers were taken into account: 
- 72a (8S*,9R*,11R*,12R*), 72b (8S*,9R*,11R*,12S*), 72c 
(8S*,9R*,11S*,12R*), 72d (8S*,9R*,11S*,12S*), 72e (8S*,9S*,11R*,12R*), 
72f (8S*,9S*,11R*,12S*), 72g (8S*,9S*,11S*,12R*), 72h 
(8S*,9S*,11S*,12S*).  
Starting from the obtained 3D structures, exhaustive conformational 
searches at the empirical molecular mechanics (MM) level with Monte Carlo 
Multiple Minimum (MCMM) method (50,000 steps) and Low mode 
Conformational Search (LMCS) method (50,000 steps) were performed, in 
order to allow a full exploration of the conformational space. Furthermore, 
molecular dynamic simulations were performed at 450, 600, 700, 750 K, with 





10 ns. A constant dielectric term of methanol, mimicking the presence of the 
solvent, was used in the calculations to reduce artefacts.  
For each diastereoisomer, all the conformers obtained from the previously 
mentioned conformational searches were minimized (PRCG, maximum 
derivative less than 0.001 kcal/mol) and compared. The “Redundant 
Conformer Elimination” module of Macromodel 10.2 was used to select non-
redundant conformers, excluding the conformers differing more than 13.0 
kJ/mol (3.11 kcal/mol) from the most energetically favored conformation and 
setting a 1.0 Å RMSD (root-mean-square deviation) minimum cut-off for 
saving structures.  
Next, the obtained conformers were optimized at quantum mechanical (QM) 
level by using the MPW1PW91 functional and the 6-31G(d) basis set. 
Experimental solvent effects (CH3OH) were reproduced using the integral 
equation formalism version of the polarizable continuum model (IEFPCM). 
After this step at the QM level, the new obtained geometries were visually 
inspected in order to remove further possible redundant conformers, and then 
those selected were accounted for the subsequent computation of the 13C and 
1H NMR chemical shifts, using the MPW1PW91 functional and the 6-31G(d,p) 
basis set and methanol IEFPCM. Final 13C and 1H NMR spectra for each of the 
investigated diastereoisomers were built considering the influence of each 
conformer on the total Boltzmann distribution taking into account the relative 
energies. Furthermore, calibrations of calculated 13C and 1H chemical shifts 
were performed following the multi-standard approach (MSTD).137,138 In 
particular, aromatic 13C and 1H chemical shifts were scaled using benzene as 
reference compound. All the other 13C and 1H calculated chemical shifts were 
scaled to TMS (tetramethylsilane).  
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